###begin article-title 0
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 54 60 <span type="species:ncbi:10090">murine</span>
Atrial arrhythmogenesis in wild-type and Scn5a+/Delta murine hearts modelling LQT3 syndrome
###end article-title 0
###begin p 1
###xml 448 453 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 518 519 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 576 577 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 686 694 682 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">positive</italic>
###xml 847 849 843 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 906 907 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 984 985 980 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1011 1012 1007 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1082 1084 1078 1080 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1119 1127 1115 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">negative</italic>
###xml 1223 1225 1219 1221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1577 1579 1573 1575 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1595 1603 1591 1599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">positive</italic>
###xml 1618 1627 1614 1623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">increased</italic>
###xml 1689 1691 1685 1687 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 488 494 <span type="species:ncbi:10090">murine</span>
Long QT(3) (LQT3) syndrome is associated with abnormal repolarisation kinetics, prolonged action potential durations (APD) and QT intervals and may lead to life-threatening ventricular arrhythmias. However, there have been few physiological studies of its effects on atrial electrophysiology. Programmed electrical stimulation and burst pacing induced atrial arrhythmic episodes in 16 out of 16 (16/16) wild-type (WT) and 7/16 genetically modified Scn5a+/Delta (KPQ) Langendorff-perfused murine hearts modelling LQT3 (P < 0.001 for both), and in 14/16 WT and 1/16 KPQ hearts (P < 0.001 for both; Fisher's exact test), respectively. The arrhythmogenic WT hearts had significantly larger positive critical intervals (CI), given by the difference between atrial effective refractory periods (AERPs) and action potential durations at 90% recovery (APD90), compared to KPQ hearts (8.1 and 3.2 ms, respectively, P < 0.001). Flecainide prevented atrial arrhythmias in all arrhythmogenic WT (P < 0.001) and KPQ hearts (P < 0.05). It prolonged the AERP to a larger extent than it did the APD90 in both WT and KPQ groups, giving negative CIs. Quinidine similarly exerted anti-arrhythmic effects, prolonged AERP over corresponding APD90 in both WT and KPQ groups. These findings, thus, demonstrate, for the first time, inhibitory effects of the KPQ mutation on atrial arrhythmogenesis and its modification by flecainide and quinidine. They attribute these findings to differences in the CI between WT and mutant hearts, in the presence or absence of these drugs. Thus, prolongation of APD90 over AERP gave positive CI values and increased atrial arrhythmogenicity whereas lengthening of AERP over APD90 reduced such CI values and produced the opposite effect.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 989 991 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 312 318 <span type="species:ncbi:10090">murine</span>
###xml 908 916 <span type="species:ncbi:9606">patients</span>
###xml 1042 1050 <span type="species:ncbi:9606">patients</span>
Atrial tachycardia (AT) is characterised by an abnormal rapid cardiac rhythm which can develop into atrial fibrillation (AF). Its clinical incidence is influenced by familial history and, therefore, genetic factors [9]. Re-entrant substrates have been implicated in such phenomena [2, 21]. In common with recent murine ventricular models for long QT syndromes (LQTS) [27, 34, 40], previous studies have attributed atrial arrhythmogenesis to decreased tissue refractoriness or alterations in action potential duration (APD) [1, 6, 24, 33, 48]. However, APD is determined by the balance between a number of inward and outward currents that flow during action potential restitution that could be specific for atrial tissue. Yet few studies have examined for the existence of or characterised atrial as opposed to ventricular arrhythmic phenotypes in LQTS models. Atrial arrhythmias were reported as uncommon in patients with the inherited LQTS who are susceptible to ventricular arrhythmias [43]. However, a recent study [14] reported that LQTS patients demonstrated abnormalities in atrial physiology similar to those found in the ventricle in the form of prolonged APD and refractory period (RP) durations and early after-depolarisations (EADs) triggering 'atrial torsade de pointes'. This suggested that electrophysiological abnormalities seen in LQTS individuals could predispose not only to ventricular but also to atrial arrhythmias. However, this study included very few LQT1, LQT2, long QT(3) (LQT3) and unidentified carriers.
###end p 4
###begin p 5
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 235 236 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 288 290 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 292 294 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 296 298 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 432 437 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 646 648 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 650 652 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 654 656 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 859 861 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 863 865 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
###xml 473 478 <span type="species:ncbi:9606">human</span>
###xml 628 634 <span type="species:ncbi:9606">humans</span>
LQT3 is one of the known LQTS variants; the causes of LQT3 include 'gain-of-function' mutations in the inactivation domain between DIII and DIV of the Scn5a gene encoding the alpha-(pore-forming) subunit of the cardiac voltage-gated Na+ channel responsible for initiating the cardiac AP [38, 46, 47]. One such, DeltaKPQ, mutation is a deletion of nine bases that code for Lys-1505, Pro-1506, Gln-1507, resulting in a prolonged APD. Scn5a+/Delta (KPQ) mutant mice modelling human LQT3 have been successfully used to demonstrate AP and QT prolongation along with torsade de pointes-like ventricular tachycardia, often observed in humans with LQT3 [25, 28, 40]. Furthermore, the cardiotropic Class I drugs, flecainide and quinidine respectively exerted anti- and pro-arrhythmic effects on KPQ hearts, but had precisely opposite effects in wild-type (WT) hearts [39, 40]. These actions correlated directly with the corresponding changes in endocardial and epicardial APDs as well as the corresponding RPs.
###end p 5
###begin p 6
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 291 297 <span type="species:ncbi:10090">murine</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
###xml 438 443 <span type="species:ncbi:9606">human</span>
###xml 747 752 <span type="species:ncbi:10090">mouse</span>
###xml 898 903 <span type="species:ncbi:10090">mouse</span>
However, in contrast to the ventricles, atria are thin-walled structures less likely to generate these marked transmural heterogeneities that have been associated with ventricular arrhythmogenesis [3, 4, 40]. Yet, there are very few studies that have investigated atrial arrhythmogenesis in murine hearts [19, 42, 45]. Finally, to date, there has not been a study investigating atrial arrhythmogenicity specifically in KPQ mice modelling human LQT3. This investigation, therefore, tests the hypothesis that factors previously known to determine arrhythmias in ventricles do not necessarily determine atrial arrhythmogenicity. It demonstrated for the first time contrasting atrial electrophysiological properties of WT and KPQ Langendorff-perfused mouse hearts modelling LQT3 syndrome and that drugs causing ventricular arrhythmogenecity do not have identical effects in atrial tissue in WT and KPQ mouse hearts.
###end p 6
###begin title 7
Methods
###end title 7
###begin title 8
Experimental animals
###end title 8
###begin p 9
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 169 173 <span type="species:ncbi:10090">Mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
WT and heterozygote Scn5a+/Delta (KPQ) mice breeding pairs both with a 129 genetic background were set up and their offspring genotyped, weaned and used for this study. Mice aged 5 to 9 months were used in all experiments. All mice were maintained in an animal house at room temperature, subjected to 12 h light-dark cycle, and had a free access to sterile rodent chow and water at all times. All procedures were in accordance with the UK Animals (Scientific Procedures) Act 1986.
###end p 9
###begin title 10
Experimental preparations
###end title 10
###begin p 11
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 454 455 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 472 473 472 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 475 476 475 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 486 487 486 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 497 498 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 585 586 585 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 592 593 592 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1017 1019 1011 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
Langendorff-perfused whole heart preparations were used for electrophysiological studies, as previously described by Balasubramaniam et al. [5] and Head et al. [12]. Animals were randomly selected and killed in accordance with Schedule 1: Animals (Scientific Procedures) Act 1986 by cervical dislocation. Whole hearts were then quickly excised and submerged in ice-cold bicarbonate-buffered Krebs-Henseleit solution prepared from (mM): 119 NaCl, 25 NaHCO3, 4.0 KCl, 1.2 KH2PO4, 1.0 MgCl2, 1.8 CaCl2, 10 glucose and 2.0 sodium pyruvate (pH 7.4). The solution was then bubbled with 95% O2-5% CO2 (British Oxygen Company, Manchester, UK). The aorta was cannulated and then sutured to a 21-gauge custom-made cannula prefilled with ice-cold buffer while the heart was fully submerged in Krebs-Henseleit solution. The preparation was then mounted onto a perfusion apparatus which allowed a warmed (37degreesC) Krebs-Henseleit buffer solution to pass through the heart via the aorta at a constant flow rate of 2.5-3.0 ml min-1 (Watson-Marlow Bredel Peristaltic pumps, model 505S, Falmouth, Cornwall, UK). Before entering the heart, the perfusate was passed through 200- and 5-mum filters (Millipore UK, Watford, UK). Hearts that regained a pink colouration and spontaneous rhythmic contractions upon warming were used in the experiments.
###end p 11
###begin title 12
Electrophysiological procedures
###end title 12
###begin p 13
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
On warming and regaining a healthy pink colour and a normal heart beat, hearts were allowed to spontaneously beat for at least 10 min before proceeding with programmed electrical stimulation (PES) [30, 31] and burst pacing (BP) as described below. Paired (1 mm inter-pole spacing) platinum stimulating and recording electrodes were positioned against the epicardial surfaces of the right and the left atrium, respectively, which allowed bipolar electrograms (BEGs) to be recorded from atria and ventricles. BEGs were amplified, band-pass filtered (30 Hz-1 kHz; Gould 2400S, Gould-Nicolet Technologies, Ilford, Essex, UK) and digitised (1401plus, Cambridge Electronic Design, Cambridge, UK) at a frequency of 5 kHz. In addition, a third electrode was placed on the basal epicardial surface of the left ventricle in order to obtain a simultaneous BEG signal from the left ventricle only. The procedure of simultaneous atrial and ventricular recording made it possible to separate contributions to electrical activity from each structure in the observed BEG recordings.
###end p 13
###begin p 14
A paired platinum pacing electrode connected to Grass S48 stimulator (Grass-Telefactor, UK, Slough, UK) was used to pace the heart at the right atrium at 3.5 V. On positioning of all electrodes, each heart was briefly paced at a frequency of 8 Hz using 2 ms square-wave stimuli to ensure consistent capture and good quality signals. Upon acquiring a clear signal, the position of the stimulation and recording electrodes was fixed.
###end p 14
###begin p 15
To assess tendencies to atrial arrhythmogenesis, two procedures were used. Firstly, each heart was subjected to PES. This consisted of drive trains of eight paced S1 beats at 8 or 10 Hz that were then followed by S2 extrastimuli every ninth beat. The S1-S2 interval was initially equal to the pacing interval and then reduced by 1 ms between successive drive trains until the preparation became refractory and no electrogram could be elicited by the S2 stimulus, or arrhythmic episode was initiated. If arrhythmia supervened, pacing was terminated in order to confirm its persistence or otherwise. Each heart was first subjected to PES stimulation conducted at 8 Hz; this was repeated three times and followed by PES stimulation conducted at 10 Hz that was also repeated three times.
###end p 15
###begin p 16
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Secondly, each heart was exposed to a modified BP protocol that was previously used to induce atrial arrhythmias in mice [19]. The alternative protocol involved delivering 25 trains of 50 stimuli imposed at high frequency (20 ms between each stimulus) to the right atrium of a spontaneously beating heart. Each successive train was delivered as soon as the heart had recovered from the preceding stimulation by returning to normal sinus rhythm.
###end p 16
###begin p 17
In addition to BEGs, atrial monophasic action potentials (MAPs) were recorded from atrioventricular (AV)-node-ablated hearts. The left atrial appendage was pressed against the clip using an epicardial MAP electrode (Linton Instruments, Harvard Apparatus). This resulted in a recording of atrial MAP signals. The heart was then paced at 8 and 10 Hz stimulation frequencies using a pacing electrode described above. MAPs were amplified, band-pass filtered (0.5 Hz-1 kHz, Gould 2400S, Gould-Nicolet Technologies, Ilford, Essex, UK) and digitised (1401plus, Cambridge Electronic Design, Cambridge, UK) at a frequency of 5 kHz.
###end p 17
###begin p 18
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
The abovementioned electrophysiological procedures were recorded in the presence and absence of pharmacological intervention. Only arrhythmias of more than six cycles in duration were included in the analysis. Atrial MAPs included in analysis satisfied previously described criteria including a rapid upstroke phase with consistent amplitude, a smooth contoured repolarisation phase and a stable baseline [8]. APDs were determined at 90% repolarisation level, where full repolarisation to baseline level was defined as 100% and the tip of each MAP upstroke as 0% repolarisation.
###end p 18
###begin title 19
Data analysis and statistics
###end title 19
###begin p 20
###xml 301 302 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
BEGs were captured and analysed using Spike5 software (Cambridge Electronic Design, Cambridge, UK). All data were imported into Microsoft EXCEL which was also used to construct graphs and figures. All data are expressed as means +/- SEM. The sets of data were compared using ANOVA (SPSS software) and P values less than 0.05 were considered significant.
###end p 20
###begin title 21
Reagents
###end title 21
###begin p 22
Flecainide and quinidine (Sigma-Aldrich, Poole, UK) were dissolved in doubly distilled water to make 1.0-mM stock solutions. Final drug concentrations to be used in the experiments (1 and 3 muM for both flecainide and quinidine) were determined by testing five different concentrations (100 nM, 1, 3, 5 and 10 muM) of the drugs. Final drug concentrations were prepared by dilution of 1.0-mM stock solutions in buffer to 10 muM first and then further dilutions to the required concentrations. Flecainide was stored in the refrigerator at 4degreesC between experiments and quinidine at room temperature with aluminium foil wrapped around a tightly sealed container to prevent light degradation. Hearts were perfused with drugs for 15-20 min prior to PES and BP.
###end p 22
###begin title 23
Results
###end title 23
###begin title 24
KPQ hearts show lower incidences and shorter durations of atrial arrhythmias under both testing procedures
###end title 24
###begin p 25
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 98 99 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 159 160 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 419 420 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 476 477 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 524 525 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 925 926 921 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1018 1019 1014 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1063 1064 1059 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1254 1256 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1258 1260 1254 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1262 1264 1258 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 1266 1268 1262 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 1772 1778 1768 1774 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1901 1902 1897 1898 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1904 1905 1900 1901 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1910 1911 1906 1907 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1913 1914 1909 1910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1933 1934 1929 1930 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1936 1937 1932 1933 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1942 1943 1938 1939 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1945 1946 1941 1942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1983 1985 1979 1981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 2121 2128 2117 2124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">stim S1</italic>
###xml 2187 2194 2183 2190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">stim S2</italic>
###xml 2197 2198 2193 2194 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 2200 2201 2196 2197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 2625 2626 2621 2622 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 2628 2629 2624 2625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2731 2732 2727 2728 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 2734 2735 2730 2731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 3202 3203 3198 3199 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 3205 3206 3201 3202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 3209 3210 3205 3206 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 3212 3213 3208 3209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 3282 3284 3278 3280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
###xml 3507 3508 3503 3504 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 3510 3511 3506 3507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 3655 3656 3651 3652 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 3658 3659 3654 3655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1778 3660 1774 3656 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Assessment of atrial arrhythmogenesis using a programmed electrical stimulation procedure. Simultaneously recorded atrial (<bold>A</bold>, <bold>B</bold> and <bold>C</bold>, <italic>a</italic>) and ventricular (<bold>A</bold>, <bold>B</bold> and <bold>C</bold>, <italic>b</italic>) BEG traces obtained from a typical <italic>WT</italic> heart in response to pacing conducted at a 10&#160;Hz stimulation frequency. The single vertical markers indicate the timing of S1 stimuli (<italic>stim S1</italic>), the double vertical markers represent S2 extra-stimuli (<italic>stim S2</italic>). <bold>A</bold> (<italic>a</italic>), Typical data obtained at the beginning of the PES procedure at a longer S1S2 interval. A succession of three S1 stimulation artefacts and their respective evoked atrial (&#8220;A&#8221;) and ventricular (&#8220;V&#8221;) electrograms are succeeded by the extrastimulus (S2) artefact and its resulting atrial electrogram (&#8220;A2&#8221;) which is then followed by the first of eight S1 stimulation artefacts and its corresponding &#8220;A&#8221; and &#8220;V&#8221; electrograms. <bold>A</bold>, <italic>b</italic> shows simultaneously recorded signals from the left ventricle and excludes the atrial contributions. <bold>B</bold> (<italic>a</italic>) Typical data obtained when atrial refractoriness is observed. The third S1 stimulation artefact is closely followed by a S1 evoked &#8220;A&#8221; electrogram and S2 stimulation artefact. It is clearly seen that the S2 premature stimulus failed to produce a corresponding &#8220;A2&#8221; atrial signal which indicates atrial refractoriness. The signal following the S2 stimulation artefact is a &#8220;V&#8221; electrogram which is confirmed by the corresponding &#8220;V&#8221; electrogram in the bottom trace (<bold>B</bold>, <italic>b</italic>). <bold>C</bold> (<italic>a</italic>), Typical data showing initiation of atrial arrhythmogenic episode (<italic>AA</italic>) in response to a premature S2 stimulus. The S1 stimulation artefact is closely followed by a S1 evoked &#8220;A&#8221; electrogram and S2 stimulation artefact which is in turn succeeded by a &#8220;V&#8221; electrogram and AT. The bottom trace (<bold>C</bold>, <italic>b</italic>) confirms the atrial origin of the tachycardia as no ventricular activity is observed at the time when atrium is tachycardic at the top trace (<bold>C</bold>, <italic>a</italic>)</p>
###xml 1778 3660 1774 3656 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Assessment of atrial arrhythmogenesis using a programmed electrical stimulation procedure. Simultaneously recorded atrial (<bold>A</bold>, <bold>B</bold> and <bold>C</bold>, <italic>a</italic>) and ventricular (<bold>A</bold>, <bold>B</bold> and <bold>C</bold>, <italic>b</italic>) BEG traces obtained from a typical <italic>WT</italic> heart in response to pacing conducted at a 10&#160;Hz stimulation frequency. The single vertical markers indicate the timing of S1 stimuli (<italic>stim S1</italic>), the double vertical markers represent S2 extra-stimuli (<italic>stim S2</italic>). <bold>A</bold> (<italic>a</italic>), Typical data obtained at the beginning of the PES procedure at a longer S1S2 interval. A succession of three S1 stimulation artefacts and their respective evoked atrial (&#8220;A&#8221;) and ventricular (&#8220;V&#8221;) electrograms are succeeded by the extrastimulus (S2) artefact and its resulting atrial electrogram (&#8220;A2&#8221;) which is then followed by the first of eight S1 stimulation artefacts and its corresponding &#8220;A&#8221; and &#8220;V&#8221; electrograms. <bold>A</bold>, <italic>b</italic> shows simultaneously recorded signals from the left ventricle and excludes the atrial contributions. <bold>B</bold> (<italic>a</italic>) Typical data obtained when atrial refractoriness is observed. The third S1 stimulation artefact is closely followed by a S1 evoked &#8220;A&#8221; electrogram and S2 stimulation artefact. It is clearly seen that the S2 premature stimulus failed to produce a corresponding &#8220;A2&#8221; atrial signal which indicates atrial refractoriness. The signal following the S2 stimulation artefact is a &#8220;V&#8221; electrogram which is confirmed by the corresponding &#8220;V&#8221; electrogram in the bottom trace (<bold>B</bold>, <italic>b</italic>). <bold>C</bold> (<italic>a</italic>), Typical data showing initiation of atrial arrhythmogenic episode (<italic>AA</italic>) in response to a premature S2 stimulus. The S1 stimulation artefact is closely followed by a S1 evoked &#8220;A&#8221; electrogram and S2 stimulation artefact which is in turn succeeded by a &#8220;V&#8221; electrogram and AT. The bottom trace (<bold>C</bold>, <italic>b</italic>) confirms the atrial origin of the tachycardia as no ventricular activity is observed at the time when atrium is tachycardic at the top trace (<bold>C</bold>, <italic>a</italic>)</p></caption>
###xml 3660 3660 3656 3656 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2008_633_Fig1_HTML" id="MO1"/>
###xml 1772 3660 1768 3656 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="26">Assessment of atrial arrhythmogenesis using a programmed electrical stimulation procedure. Simultaneously recorded atrial (<bold>A</bold>, <bold>B</bold> and <bold>C</bold>, <italic>a</italic>) and ventricular (<bold>A</bold>, <bold>B</bold> and <bold>C</bold>, <italic>b</italic>) BEG traces obtained from a typical <italic>WT</italic> heart in response to pacing conducted at a 10&#160;Hz stimulation frequency. The single vertical markers indicate the timing of S1 stimuli (<italic>stim S1</italic>), the double vertical markers represent S2 extra-stimuli (<italic>stim S2</italic>). <bold>A</bold> (<italic>a</italic>), Typical data obtained at the beginning of the PES procedure at a longer S1S2 interval. A succession of three S1 stimulation artefacts and their respective evoked atrial (&#8220;A&#8221;) and ventricular (&#8220;V&#8221;) electrograms are succeeded by the extrastimulus (S2) artefact and its resulting atrial electrogram (&#8220;A2&#8221;) which is then followed by the first of eight S1 stimulation artefacts and its corresponding &#8220;A&#8221; and &#8220;V&#8221; electrograms. <bold>A</bold>, <italic>b</italic> shows simultaneously recorded signals from the left ventricle and excludes the atrial contributions. <bold>B</bold> (<italic>a</italic>) Typical data obtained when atrial refractoriness is observed. The third S1 stimulation artefact is closely followed by a S1 evoked &#8220;A&#8221; electrogram and S2 stimulation artefact. It is clearly seen that the S2 premature stimulus failed to produce a corresponding &#8220;A2&#8221; atrial signal which indicates atrial refractoriness. The signal following the S2 stimulation artefact is a &#8220;V&#8221; electrogram which is confirmed by the corresponding &#8220;V&#8221; electrogram in the bottom trace (<bold>B</bold>, <italic>b</italic>). <bold>C</bold> (<italic>a</italic>), Typical data showing initiation of atrial arrhythmogenic episode (<italic>AA</italic>) in response to a premature S2 stimulus. The S1 stimulation artefact is closely followed by a S1 evoked &#8220;A&#8221; electrogram and S2 stimulation artefact which is in turn succeeded by a &#8220;V&#8221; electrogram and AT. The bottom trace (<bold>C</bold>, <italic>b</italic>) confirms the atrial origin of the tachycardia as no ventricular activity is observed at the time when atrium is tachycardic at the top trace (<bold>C</bold>, <italic>a</italic>)</p></caption><graphic position="anchor" xlink:href="424_2008_633_Fig1_HTML" id="MO1"/></fig>
###xml 3660 3666 3656 3662 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 3896 3897 3892 3893 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 4004 4005 4000 4001 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 4054 4056 4050 4052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
###xml 4095 4096 4091 4092 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 3666 4097 3662 4093 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Assessment of atrial arrhythmogenesis using atrial burst pacing. Typical baseline sinus rhythm recording from a WT heart, where each regularly occurring atrial (&#8220;A&#8221;) signal is followed by a corresponding ventricular (&#8220;V&#8221;) signal (<bold>A</bold>). A train of 50 high frequency S1 stimuli results in either an immediate return to a normal sinus rhythm (<bold>B</bold>) or initiation of an atrial arrhythmic episode (<italic>AA</italic>) with irregular ventricular activity (<bold>C</bold>)</p>
###xml 3666 4097 3662 4093 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">Assessment of atrial arrhythmogenesis using atrial burst pacing. Typical baseline sinus rhythm recording from a WT heart, where each regularly occurring atrial (&#8220;A&#8221;) signal is followed by a corresponding ventricular (&#8220;V&#8221;) signal (<bold>A</bold>). A train of 50 high frequency S1 stimuli results in either an immediate return to a normal sinus rhythm (<bold>B</bold>) or initiation of an atrial arrhythmic episode (<italic>AA</italic>) with irregular ventricular activity (<bold>C</bold>)</p></caption>
###xml 4097 4097 4093 4093 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2008_633_Fig2_HTML" id="MO2"/>
###xml 3660 4097 3656 4093 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="27">Assessment of atrial arrhythmogenesis using atrial burst pacing. Typical baseline sinus rhythm recording from a WT heart, where each regularly occurring atrial (&#8220;A&#8221;) signal is followed by a corresponding ventricular (&#8220;V&#8221;) signal (<bold>A</bold>). A train of 50 high frequency S1 stimuli results in either an immediate return to a normal sinus rhythm (<bold>B</bold>) or initiation of an atrial arrhythmic episode (<italic>AA</italic>) with irregular ventricular activity (<bold>C</bold>)</p></caption><graphic position="anchor" xlink:href="424_2008_633_Fig2_HTML" id="MO2"/></fig>
###xml 145 151 <span type="species:ncbi:10090">murine</span>
Two techniques were used to assess atrial arrhythmogenic tendency in each WT (n = 16; Figs. 1 and 2) and genetically modified Scn5a+/Delta (KPQ) murine heart (n = 16) using BEG recordings. First, three cycles of a PES procedure conducted at a pacing frequency of 8 Hz imposed trains of eight pacing (S1) stimuli each followed by a ninth S2 extra stimulus at progressively decreasing S1S2 intervals (exemplified by Fig. 1A) until either atrial refractoriness was reached (Fig. 1B) or atrial arrhythmogenesis took place (Fig. 1C). The procedure was then similarly repeated three times at a pacing frequency of 10 Hz. This procedure permitted both assessment of atrial arrhythmogenic tendency and determination of atrial RPs. Secondly, an atrial BP procedure delivered 25 trains of 50 S1 stimuli at a high frequency (corresponding to a S1S1 coupling interval of 20 ms) to the right atrium of a spontaneously beating heart (Fig. 2A). This was followed by an assessment for either an immediate return to sinus rhythm (Fig. 2B) or the onset of atrial arrhythmias (Fig. 2C). Each successive train was delivered once the heart had regained its normal sinus rhythm. The present protocols, thus, differed from our previous studies on ventricular arrhythmogenesis [12, 27, 39, 40] in requiring hearts to be paced from the atria rather than the ventricles. In some hearts, such higher pacing rates resulted in a gradual development of an AV block particularly at the higher (10 Hz) pacing rate. Nevertheless, withdrawal of the regular pacing allowed a resumption of intrinsic activity and permitted restoration of normal 1:1 AV conduction. Such AV block was also observed during both the PES and the BP procedures. These findings could relate to longer refractoriness in the AV node. Fig. 1Assessment of atrial arrhythmogenesis using a programmed electrical stimulation procedure. Simultaneously recorded atrial (A, B and C, a) and ventricular (A, B and C, b) BEG traces obtained from a typical WT heart in response to pacing conducted at a 10 Hz stimulation frequency. The single vertical markers indicate the timing of S1 stimuli (stim S1), the double vertical markers represent S2 extra-stimuli (stim S2). A (a), Typical data obtained at the beginning of the PES procedure at a longer S1S2 interval. A succession of three S1 stimulation artefacts and their respective evoked atrial ("A") and ventricular ("V") electrograms are succeeded by the extrastimulus (S2) artefact and its resulting atrial electrogram ("A2") which is then followed by the first of eight S1 stimulation artefacts and its corresponding "A" and "V" electrograms. A, b shows simultaneously recorded signals from the left ventricle and excludes the atrial contributions. B (a) Typical data obtained when atrial refractoriness is observed. The third S1 stimulation artefact is closely followed by a S1 evoked "A" electrogram and S2 stimulation artefact. It is clearly seen that the S2 premature stimulus failed to produce a corresponding "A2" atrial signal which indicates atrial refractoriness. The signal following the S2 stimulation artefact is a "V" electrogram which is confirmed by the corresponding "V" electrogram in the bottom trace (B, b). C (a), Typical data showing initiation of atrial arrhythmogenic episode (AA) in response to a premature S2 stimulus. The S1 stimulation artefact is closely followed by a S1 evoked "A" electrogram and S2 stimulation artefact which is in turn succeeded by a "V" electrogram and AT. The bottom trace (C, b) confirms the atrial origin of the tachycardia as no ventricular activity is observed at the time when atrium is tachycardic at the top trace (C, a)Fig. 2Assessment of atrial arrhythmogenesis using atrial burst pacing. Typical baseline sinus rhythm recording from a WT heart, where each regularly occurring atrial ("A") signal is followed by a corresponding ventricular ("V") signal (A). A train of 50 high frequency S1 stimuli results in either an immediate return to a normal sinus rhythm (B) or initiation of an atrial arrhythmic episode (AA) with irregular ventricular activity (C)
###end p 25
###begin p 26
###xml 123 124 123 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 126 127 126 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 132 133 132 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 155 156 155 156 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 158 159 158 159 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 164 165 164 165 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 205 207 205 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 343 350 343 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">stim S1</italic>
###xml 409 416 409 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">stim S2</italic>
###xml 419 420 419 420 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 422 423 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 847 848 847 848 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 850 851 850 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 953 954 953 954 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 956 957 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1424 1425 1424 1425 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1427 1428 1427 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1431 1432 1431 1432 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1434 1435 1434 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1504 1506 1504 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
###xml 1729 1730 1729 1730 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1732 1733 1732 1733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1877 1878 1877 1878 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1880 1881 1880 1881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
Assessment of atrial arrhythmogenesis using a programmed electrical stimulation procedure. Simultaneously recorded atrial (A, B and C, a) and ventricular (A, B and C, b) BEG traces obtained from a typical WT heart in response to pacing conducted at a 10 Hz stimulation frequency. The single vertical markers indicate the timing of S1 stimuli (stim S1), the double vertical markers represent S2 extra-stimuli (stim S2). A (a), Typical data obtained at the beginning of the PES procedure at a longer S1S2 interval. A succession of three S1 stimulation artefacts and their respective evoked atrial ("A") and ventricular ("V") electrograms are succeeded by the extrastimulus (S2) artefact and its resulting atrial electrogram ("A2") which is then followed by the first of eight S1 stimulation artefacts and its corresponding "A" and "V" electrograms. A, b shows simultaneously recorded signals from the left ventricle and excludes the atrial contributions. B (a) Typical data obtained when atrial refractoriness is observed. The third S1 stimulation artefact is closely followed by a S1 evoked "A" electrogram and S2 stimulation artefact. It is clearly seen that the S2 premature stimulus failed to produce a corresponding "A2" atrial signal which indicates atrial refractoriness. The signal following the S2 stimulation artefact is a "V" electrogram which is confirmed by the corresponding "V" electrogram in the bottom trace (B, b). C (a), Typical data showing initiation of atrial arrhythmogenic episode (AA) in response to a premature S2 stimulus. The S1 stimulation artefact is closely followed by a S1 evoked "A" electrogram and S2 stimulation artefact which is in turn succeeded by a "V" electrogram and AT. The bottom trace (C, b) confirms the atrial origin of the tachycardia as no ventricular activity is observed at the time when atrium is tachycardic at the top trace (C, a)
###end p 26
###begin p 27
###xml 230 231 230 231 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 338 339 338 339 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 388 390 388 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
###xml 429 430 429 430 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
Assessment of atrial arrhythmogenesis using atrial burst pacing. Typical baseline sinus rhythm recording from a WT heart, where each regularly occurring atrial ("A") signal is followed by a corresponding ventricular ("V") signal (A). A train of 50 high frequency S1 stimuli results in either an immediate return to a normal sinus rhythm (B) or initiation of an atrial arrhythmic episode (AA) with irregular ventricular activity (C)
###end p 27
###begin p 28
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 532 533 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 859 860 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1355 1362 1355 1362 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1362 1406 1362 1406 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Atrial arrythmogenicity in WT and KPQ hearts</p>
###xml 1362 1406 1362 1406 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Atrial arrythmogenicity in WT and KPQ hearts</p></caption>
###xml 1406 1414 1406 1414 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Genotype</th>
###xml 1414 1416 1414 1416 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">WT</th>
###xml 1416 1419 1416 1419 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">KPQ</th>
###xml 1406 1419 1406 1419 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Genotype</th><th colspan="2">WT</th><th colspan="2">KPQ</th></tr>
###xml 1419 1443 1419 1443 <th xmlns:xlink="http://www.w3.org/1999/xlink">No of hearts showing AAs</th>
###xml 1443 1481 1443 1481 <th xmlns:xlink="http://www.w3.org/1999/xlink">Mean overall duration of AA/heart (ms)</th>
###xml 1481 1505 1481 1505 <th xmlns:xlink="http://www.w3.org/1999/xlink">No of hearts showing AAs</th>
###xml 1505 1543 1505 1543 <th xmlns:xlink="http://www.w3.org/1999/xlink">Mean overall duration of AA/heart (ms)</th>
###xml 1419 1543 1419 1543 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>No of hearts showing AAs</th><th>Mean overall duration of AA/heart (ms)</th><th>No of hearts showing AAs</th><th>Mean overall duration of AA/heart (ms)</th></tr>
###xml 1406 1543 1406 1543 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Genotype</th><th colspan="2">WT</th><th colspan="2">KPQ</th></tr><tr><th>No of hearts showing AAs</th><th>Mean overall duration of AA/heart (ms)</th><th>No of hearts showing AAs</th><th>Mean overall duration of AA/heart (ms)</th></tr></thead>
###xml 1543 1553 1543 1553 <td xmlns:xlink="http://www.w3.org/1999/xlink">PES (8&#160;Hz)</td>
###xml 1553 1558 1553 1558 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">16/16</td>
###xml 1572 1573 1570 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1558 1579 1558 1577 <td xmlns:xlink="http://www.w3.org/1999/xlink">1986&#8201;&#177;&#8201;839 (<italic>n</italic>&#8201;=&#8201;16)</td>
###xml 1579 1583 1577 1581 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">7/16</td>
###xml 1596 1597 1592 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1583 1602 1581 1598 <td xmlns:xlink="http://www.w3.org/1999/xlink">602&#8201;&#177;&#8201;189 (<italic>n</italic>&#8201;=&#8201;7)</td>
###xml 1543 1602 1543 1598 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>PES (8&#160;Hz)</td><td char="/" align="char">16/16</td><td>1986&#8201;&#177;&#8201;839 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">7/16</td><td>602&#8201;&#177;&#8201;189 (<italic>n</italic>&#8201;=&#8201;7)</td></tr>
###xml 1602 1613 1598 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink">PES (10&#160;Hz)</td>
###xml 1613 1618 1609 1614 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">16/16</td>
###xml 1632 1633 1626 1627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1618 1639 1614 1633 <td xmlns:xlink="http://www.w3.org/1999/xlink">1524&#8201;&#177;&#8201;505 (<italic>n</italic>&#8201;=&#8201;16)</td>
###xml 1639 1643 1633 1637 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">7/16</td>
###xml 1656 1657 1648 1649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1643 1662 1637 1654 <td xmlns:xlink="http://www.w3.org/1999/xlink">859&#8201;&#177;&#8201;354 (<italic>n</italic>&#8201;=&#8201;7)</td>
###xml 1602 1662 1598 1654 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>PES (10&#160;Hz)</td><td char="/" align="char">16/16</td><td>1524&#8201;&#177;&#8201;505 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">7/16</td><td>859&#8201;&#177;&#8201;354 (<italic>n</italic>&#8201;=&#8201;7)</td></tr>
###xml 1662 1664 1654 1656 <td xmlns:xlink="http://www.w3.org/1999/xlink">BP</td>
###xml 1664 1669 1656 1661 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">14/16</td>
###xml 1684 1685 1674 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1669 1691 1661 1681 <td xmlns:xlink="http://www.w3.org/1999/xlink">3560&#8201;&#177;&#8201;1411 (<italic>n</italic>&#8201;=&#8201;16)</td>
###xml 1691 1695 1681 1685 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">1/16</td>
###xml 1700 1701 1690 1691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1695 1706 1685 1696 <td xmlns:xlink="http://www.w3.org/1999/xlink">240 (<italic>n</italic>&#8201;=&#8201;1)</td>
###xml 1662 1706 1654 1696 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BP</td><td char="/" align="char">14/16</td><td>3560&#8201;&#177;&#8201;1411 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">1/16</td><td>240 (<italic>n</italic>&#8201;=&#8201;1)</td></tr>
###xml 1543 1706 1543 1696 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>PES (8&#160;Hz)</td><td char="/" align="char">16/16</td><td>1986&#8201;&#177;&#8201;839 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">7/16</td><td>602&#8201;&#177;&#8201;189 (<italic>n</italic>&#8201;=&#8201;7)</td></tr><tr><td>PES (10&#160;Hz)</td><td char="/" align="char">16/16</td><td>1524&#8201;&#177;&#8201;505 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">7/16</td><td>859&#8201;&#177;&#8201;354 (<italic>n</italic>&#8201;=&#8201;7)</td></tr><tr><td>BP</td><td char="/" align="char">14/16</td><td>3560&#8201;&#177;&#8201;1411 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">1/16</td><td>240 (<italic>n</italic>&#8201;=&#8201;1)</td></tr></tbody>
###xml 1406 1706 1406 1696 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Genotype</th><th colspan="2">WT</th><th colspan="2">KPQ</th></tr><tr><th>No of hearts showing AAs</th><th>Mean overall duration of AA/heart (ms)</th><th>No of hearts showing AAs</th><th>Mean overall duration of AA/heart (ms)</th></tr></thead><tbody><tr><td>PES (8&#160;Hz)</td><td char="/" align="char">16/16</td><td>1986&#8201;&#177;&#8201;839 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">7/16</td><td>602&#8201;&#177;&#8201;189 (<italic>n</italic>&#8201;=&#8201;7)</td></tr><tr><td>PES (10&#160;Hz)</td><td char="/" align="char">16/16</td><td>1524&#8201;&#177;&#8201;505 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">7/16</td><td>859&#8201;&#177;&#8201;354 (<italic>n</italic>&#8201;=&#8201;7)</td></tr><tr><td>BP</td><td char="/" align="char">14/16</td><td>3560&#8201;&#177;&#8201;1411 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">1/16</td><td>240 (<italic>n</italic>&#8201;=&#8201;1)</td></tr></tbody></table>
###xml 1720 1721 1710 1711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1737 1738 1727 1728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1924 1925 1912 1913 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2025 2026 2013 2014 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2052 2053 2040 2041 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2055 2056 2043 2044 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1706 2147 1696 2135 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Number of WT (<italic>n</italic>&#8201;=&#8201;16) and KPQ (<italic>n</italic>&#8201;=&#8201;16) hearts that showed one or more episodes of atrial arrhythmias during PES and BP testing procedures and the mean overall durations (&#177; SEM) of such AA episodes. Both the number (m<sub>1</sub>) of hearts that displayed AA and the total number of hearts used for the specific test procedure (m<sub>2</sub>) are shown (in the form m<sub>1</sub>/m<sub>2</sub>). For example, &#8220;7/16&#8221; indicates that seven hearts were arrhythmic out of 16 hearts tested)</p>
###xml 2147 2149 2135 2137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 2165 2170 2153 2158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 2179 2182 2163 2166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PES</italic>
###xml 2218 2220 2202 2204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BP</italic>
###xml 2147 2233 2135 2217 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing</p>
###xml 1706 2233 1696 2217 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Number of WT (<italic>n</italic>&#8201;=&#8201;16) and KPQ (<italic>n</italic>&#8201;=&#8201;16) hearts that showed one or more episodes of atrial arrhythmias during PES and BP testing procedures and the mean overall durations (&#177; SEM) of such AA episodes. Both the number (m<sub>1</sub>) of hearts that displayed AA and the total number of hearts used for the specific test procedure (m<sub>2</sub>) are shown (in the form m<sub>1</sub>/m<sub>2</sub>). For example, &#8220;7/16&#8221; indicates that seven hearts were arrhythmic out of 16 hearts tested)</p><p textid="31"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing</p></table-wrap-foot>
###xml 1355 2233 1355 2217 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="29">Atrial arrythmogenicity in WT and KPQ hearts</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Genotype</th><th colspan="2">WT</th><th colspan="2">KPQ</th></tr><tr><th>No of hearts showing AAs</th><th>Mean overall duration of AA/heart (ms)</th><th>No of hearts showing AAs</th><th>Mean overall duration of AA/heart (ms)</th></tr></thead><tbody><tr><td>PES (8&#160;Hz)</td><td char="/" align="char">16/16</td><td>1986&#8201;&#177;&#8201;839 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">7/16</td><td>602&#8201;&#177;&#8201;189 (<italic>n</italic>&#8201;=&#8201;7)</td></tr><tr><td>PES (10&#160;Hz)</td><td char="/" align="char">16/16</td><td>1524&#8201;&#177;&#8201;505 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">7/16</td><td>859&#8201;&#177;&#8201;354 (<italic>n</italic>&#8201;=&#8201;7)</td></tr><tr><td>BP</td><td char="/" align="char">14/16</td><td>3560&#8201;&#177;&#8201;1411 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="/" align="char">1/16</td><td>240 (<italic>n</italic>&#8201;=&#8201;1)</td></tr></tbody></table><table-wrap-foot><p textid="30">Number of WT (<italic>n</italic>&#8201;=&#8201;16) and KPQ (<italic>n</italic>&#8201;=&#8201;16) hearts that showed one or more episodes of atrial arrhythmias during PES and BP testing procedures and the mean overall durations (&#177; SEM) of such AA episodes. Both the number (m<sub>1</sub>) of hearts that displayed AA and the total number of hearts used for the specific test procedure (m<sub>2</sub>) are shown (in the form m<sub>1</sub>/m<sub>2</sub>). For example, &#8220;7/16&#8221; indicates that seven hearts were arrhythmic out of 16 hearts tested)</p><p textid="31"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing</p></table-wrap-foot></table-wrap>
Table 1 demonstrates lower levels of atrial arrhythmogenic tendency in KPQ (n = 16) compared to WT hearts (n = 16) with all three test procedures. Firstly, all 16 WT hearts showed at least one arrhythmic episode during PES conducted at stimulation frequencies of either 8 or 10 Hz. In contrast, only seven KPQ hearts displayed such arrhythmogenic tendency with the same procedures. Fisher's exact test accordingly confirmed highly significant differences for atrial arrhythmogenicity between the two groups for both PES procedures (P < 0.001 in both cases). BP was less effective in inducing arrhythmogenesis in either group. Nevertheless, it also yielded clear-cut differences between numbers of WT (14 out of 16) and KPQ hearts (one out of 16) showing atrial arrhythmias, similarly giving highly significant differences between the two experimental groups (P < 0.001). Secondly, where arrhythmic episodes did occur, they showed longer durations in the WT than in the KPQ hearts through all three procedures, but with a larger spread in values particularly in the WT group, which is reflected in the SEM. Therefore, it was necessary to perform further breakdowns of the arrhythmic frequencies. These analyses that followed provided closer measures of the mean incidence of atrial arrhythmias lasting six or more cycles for each heart and their severity. Table 1Atrial arrythmogenicity in WT and KPQ heartsGenotypeWTKPQNo of hearts showing AAsMean overall duration of AA/heart (ms)No of hearts showing AAsMean overall duration of AA/heart (ms)PES (8 Hz)16/161986 +/- 839 (n = 16)7/16602 +/- 189 (n = 7)PES (10 Hz)16/161524 +/- 505 (n = 16)7/16859 +/- 354 (n = 7)BP14/163560 +/- 1411 (n = 16)1/16240 (n = 1)Number of WT (n = 16) and KPQ (n = 16) hearts that showed one or more episodes of atrial arrhythmias during PES and BP testing procedures and the mean overall durations (+/- SEM) of such AA episodes. Both the number (m1) of hearts that displayed AA and the total number of hearts used for the specific test procedure (m2) are shown (in the form m1/m2). For example, "7/16" indicates that seven hearts were arrhythmic out of 16 hearts tested)WT wild-type, KPQ Scn5a+/Delta, PES programmed electrical stimulation, BP burst pacing
###end p 28
###begin p 29
Atrial arrythmogenicity in WT and KPQ hearts
###end p 29
###begin p 30
###xml 14 15 14 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 31 32 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 218 219 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 319 320 317 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 346 347 344 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 349 350 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Number of WT (n = 16) and KPQ (n = 16) hearts that showed one or more episodes of atrial arrhythmias during PES and BP testing procedures and the mean overall durations (+/- SEM) of such AA episodes. Both the number (m1) of hearts that displayed AA and the total number of hearts used for the specific test procedure (m2) are shown (in the form m1/m2). For example, "7/16" indicates that seven hearts were arrhythmic out of 16 hearts tested)
###end p 30
###begin p 31
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 32 35 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PES</italic>
###xml 71 73 67 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BP</italic>
WT wild-type, KPQ Scn5a+/Delta, PES programmed electrical stimulation, BP burst pacing
###end p 31
###begin p 32
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 504 510 504 510 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 623 624 623 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 628 629 628 629 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 630 631 630 631 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 646 647 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 651 652 651 652 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 653 654 653 654 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 690 700 690 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">empty bars</italic>
###xml 718 729 718 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">filled bars</italic>
###xml 758 759 758 759 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 761 762 761 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 767 768 767 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 781 782 781 782 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 784 785 784 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 790 791 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 825 826 825 826 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 828 829 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 834 835 834 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 902 903 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 914 915 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 931 932 931 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1009 1011 1009 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 1013 1014 1013 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1025 1028 1025 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KPQ</italic>
###xml 1030 1031 1030 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 510 1044 510 1044 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Overall and average incidence of atrial arrhythmic episodes (AAs) per heart in WT and KPQ preparations. Overall (<italic>a</italic> in <bold>A</bold>&#8211;<bold>C</bold>) and average (<italic>b</italic> in <bold>A</bold>&#8211;<bold>C</bold>) incidence of AAs per heart in WT (<italic>empty bars</italic>) and KPQ hearts (<italic>filled bars</italic>) for PES conducted at 8&#160;Hz (<bold>A</bold>, <italic>a</italic> and <italic>b</italic>) and 10&#160;Hz (<bold>B</bold>, <italic>a</italic> and <italic>b</italic>) stimulation frequencies and BP (<bold>C</bold>, <italic>a</italic> and <italic>b</italic>). The results of one-way ANOVA for correlated samples are shown (*<italic>P</italic>&#8201;&lt;&#8201;0.05, **<italic>P</italic>&#8201;&lt;&#8201;0.005 and ***<italic>P</italic>&#8201;&lt;&#8201;0.0005) and compare average and overall incidence of AA per heart between <italic>WT</italic> (<italic>n</italic>&#8201;=&#8201;16) and <italic>KPQ</italic> (<italic>n</italic>&#8201;=&#8201;16) groups</p>
###xml 510 1044 510 1044 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Overall and average incidence of atrial arrhythmic episodes (AAs) per heart in WT and KPQ preparations. Overall (<italic>a</italic> in <bold>A</bold>&#8211;<bold>C</bold>) and average (<italic>b</italic> in <bold>A</bold>&#8211;<bold>C</bold>) incidence of AAs per heart in WT (<italic>empty bars</italic>) and KPQ hearts (<italic>filled bars</italic>) for PES conducted at 8&#160;Hz (<bold>A</bold>, <italic>a</italic> and <italic>b</italic>) and 10&#160;Hz (<bold>B</bold>, <italic>a</italic> and <italic>b</italic>) stimulation frequencies and BP (<bold>C</bold>, <italic>a</italic> and <italic>b</italic>). The results of one-way ANOVA for correlated samples are shown (*<italic>P</italic>&#8201;&lt;&#8201;0.05, **<italic>P</italic>&#8201;&lt;&#8201;0.005 and ***<italic>P</italic>&#8201;&lt;&#8201;0.0005) and compare average and overall incidence of AA per heart between <italic>WT</italic> (<italic>n</italic>&#8201;=&#8201;16) and <italic>KPQ</italic> (<italic>n</italic>&#8201;=&#8201;16) groups</p></caption>
###xml 1044 1044 1044 1044 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2008_633_Fig3_HTML" id="MO3"/>
###xml 504 1044 504 1044 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="33">Overall and average incidence of atrial arrhythmic episodes (AAs) per heart in WT and KPQ preparations. Overall (<italic>a</italic> in <bold>A</bold>&#8211;<bold>C</bold>) and average (<italic>b</italic> in <bold>A</bold>&#8211;<bold>C</bold>) incidence of AAs per heart in WT (<italic>empty bars</italic>) and KPQ hearts (<italic>filled bars</italic>) for PES conducted at 8&#160;Hz (<bold>A</bold>, <italic>a</italic> and <italic>b</italic>) and 10&#160;Hz (<bold>B</bold>, <italic>a</italic> and <italic>b</italic>) stimulation frequencies and BP (<bold>C</bold>, <italic>a</italic> and <italic>b</italic>). The results of one-way ANOVA for correlated samples are shown (*<italic>P</italic>&#8201;&lt;&#8201;0.05, **<italic>P</italic>&#8201;&lt;&#8201;0.005 and ***<italic>P</italic>&#8201;&lt;&#8201;0.0005) and compare average and overall incidence of AA per heart between <italic>WT</italic> (<italic>n</italic>&#8201;=&#8201;16) and <italic>KPQ</italic> (<italic>n</italic>&#8201;=&#8201;16) groups</p></caption><graphic position="anchor" xlink:href="424_2008_633_Fig3_HTML" id="MO3"/></fig>
A third measure describing the mean overall incidence of atrial arrhthymogenesis was, therefore, obtained for each heart in the WT and mutant groups subject to each of the test procedures (Fig. 3). The incidence of atrial arrrhythmogenesis following each pulse train during the three cycles of PES at 8 and 10 Hz, respectively (Fig. 3A and B), as well as during the 25 burst pacing procedures were obtained for each heart (Fig. 3C). This permitted mean values to be obtained for each experimental group. Fig. 3Overall and average incidence of atrial arrhythmic episodes (AAs) per heart in WT and KPQ preparations. Overall (a in A-C) and average (b in A-C) incidence of AAs per heart in WT (empty bars) and KPQ hearts (filled bars) for PES conducted at 8 Hz (A, a and b) and 10 Hz (B, a and b) stimulation frequencies and BP (C, a and b). The results of one-way ANOVA for correlated samples are shown (*P < 0.05, **P < 0.005 and ***P < 0.0005) and compare average and overall incidence of AA per heart between WT (n = 16) and KPQ (n = 16) groups
###end p 32
###begin p 33
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 118 119 118 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 120 121 120 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 136 137 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 141 142 141 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 143 144 143 144 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 180 190 180 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">empty bars</italic>
###xml 208 219 208 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">filled bars</italic>
###xml 248 249 248 249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 251 252 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 271 272 271 272 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 280 281 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 315 316 315 316 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 324 325 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 404 405 404 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 421 422 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 499 501 499 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 503 504 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 515 518 515 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KPQ</italic>
###xml 520 521 520 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Overall and average incidence of atrial arrhythmic episodes (AAs) per heart in WT and KPQ preparations. Overall (a in A-C) and average (b in A-C) incidence of AAs per heart in WT (empty bars) and KPQ hearts (filled bars) for PES conducted at 8 Hz (A, a and b) and 10 Hz (B, a and b) stimulation frequencies and BP (C, a and b). The results of one-way ANOVA for correlated samples are shown (*P < 0.05, **P < 0.005 and ***P < 0.0005) and compare average and overall incidence of AA per heart between WT (n = 16) and KPQ (n = 16) groups
###end p 33
###begin p 34
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 148 149 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 191 192 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 223 224 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 286 287 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 432 433 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 482 483 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 30 36 <span type="species:ncbi:10090">murine</span>
Figure 3A demonstrates the WT murine hearts (n = 16) showed significantly higher mean overall incidences of arrhythmic episodes per heart than KPQ (n = 16) hearts during PES whether at 8 Hz (P = 0.01; Fig. 3A, a) or 10 Hz (P < 0.0001; Fig. 3B, a) stimulation frequencies and during BP (P = 0.0007; Fig. 3C, a). Furthermore, arrhythmic episodes were significantly more frequent in WT hearts paced at the higher frequency during PES (P = 0.007); this was not the case for KPQ hearts (P > 0.05).
###end p 34
###begin p 35
###xml 232 233 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 249 250 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Finally, such arrhythmic episodes were sorted by duration (atrial arrhythmia lasting </= 1 s; 1.1-5.0 s; 5.1-10 s; and 10.1 s and longer). This provided mean incidences of atrial arrhythmias within each category within the two, WT (n = 16) and KPQ (n = 16) experimental groups.
###end p 35
###begin p 36
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 244 245 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 455 456 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 476 477 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 496 497 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 679 680 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 772 773 770 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Figure 3 also shows that for both, PES and BP, procedures, and both experimental groups, a significant proportion of atrial arrhythmias observed fell into a category with the lowest range of arrhythmic durations (episodes lasting </= 1 s; Fig. 3A-C, panel b). However, the mean incidences of arrhythmic episodes per heart for this category was significantly lower in the KPQ than the WT group whether PES was conducted at stimulation frequencies of 8 Hz (P = 0.03) and 10 Hz (P < 0.0001) and BP (P = 0.02). The mean incidence of arrhythmic episodes per heart for arrhythmias lasting between 1.1-5.0 and 5.1-10.0 s was also significantly lower in KPQ hearts for the BP procedure (P = 0.03 for both), and for arrhythmias lasting 10.1 s and longer for PES conducted at 8 Hz (P = 0.05). Finally, no KPQ hearts displayed arrhythmias lasting more than 5.1 s whereas we observed a total number of 24 separate episodes of atrial arrhythmias of this duration; these occurred in six WT hearts during both experimental procedures.
###end p 36
###begin title 37
Flecainide and quinidine both inhibit atrial arrhythmogenesis
###end title 37
###begin p 38
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 238 244 <span type="species:ncbi:10090">murine</span>
The experiments then went on to compare the effects of quinidine and flecainide on atrial arrhythmogenesis. This yielded patterns of action that contrasted with previous reports of these agents on ventricular arrhythmogenesis in the same murine system [39, 40].
###end p 38
###begin p 39
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 310 311 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 443 444 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 691 692 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 805 812 801 808 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 812 940 808 935 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of flecainide (1 and 3&#160;&#956;M)</p>
###xml 812 940 808 935 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of flecainide (1 and 3&#160;&#956;M)</p></caption>
###xml 940 948 935 943 <th xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</th>
###xml 948 950 943 945 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">WT</th>
###xml 950 953 945 948 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">KPQ</th>
###xml 940 953 935 948 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Genotype</th><th colspan="3">WT</th><th colspan="3">KPQ</th></tr>
###xml 953 962 948 957 <th xmlns:xlink="http://www.w3.org/1999/xlink">Condition</th>
###xml 962 969 957 964 <th xmlns:xlink="http://www.w3.org/1999/xlink">Control</th>
###xml 969 985 964 979 <th xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 1&#160;&#956;M</th>
###xml 985 1001 979 994 <th xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 3&#160;&#956;M</th>
###xml 1001 1008 994 1001 <th xmlns:xlink="http://www.w3.org/1999/xlink">Control</th>
###xml 1008 1024 1001 1016 <th xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 1&#160;&#956;M</th>
###xml 1024 1040 1016 1031 <th xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 3&#160;&#956;M</th>
###xml 953 1040 948 1031 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Condition</th><th>Control</th><th>Flecainide 1&#160;&#956;M</th><th>Flecainide 3&#160;&#956;M</th><th>Control</th><th>Flecainide 1&#160;&#956;M</th><th>Flecainide 3&#160;&#956;M</th></tr>
###xml 940 1040 935 1031 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Genotype</th><th colspan="3">WT</th><th colspan="3">KPQ</th></tr><tr><th>Condition</th><th>Control</th><th>Flecainide 1&#160;&#956;M</th><th>Flecainide 3&#160;&#956;M</th><th>Control</th><th>Flecainide 1&#160;&#956;M</th><th>Flecainide 3&#160;&#956;M</th></tr></thead>
###xml 1040 1050 1031 1041 <td xmlns:xlink="http://www.w3.org/1999/xlink">PES (8&#160;Hz)</td>
###xml 1050 1055 1041 1046 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">11/11</td>
###xml 1055 1058 1046 1049 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">4/6</td>
###xml 1058 1061 1049 1052 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/5</td>
###xml 1061 1064 1052 1055 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">5/6</td>
###xml 1064 1067 1055 1058 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/6</td>
###xml 1067 1068 1058 1059 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1040 1068 1031 1059 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>PES (8&#160;Hz)</td><td char="/" align="char">11/11</td><td char="/" align="char">4/6</td><td char="/" align="char">0/5</td><td char="/" align="char">5/6</td><td char="/" align="char">0/6</td><td>X</td></tr>
###xml 1068 1079 1059 1070 <td xmlns:xlink="http://www.w3.org/1999/xlink">PES (10&#160;Hz)</td>
###xml 1079 1084 1070 1075 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">11/11</td>
###xml 1084 1087 1075 1078 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">2/6</td>
###xml 1087 1090 1078 1081 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/5</td>
###xml 1090 1093 1081 1084 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">4/6</td>
###xml 1093 1096 1084 1087 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/6</td>
###xml 1096 1097 1087 1088 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1068 1097 1059 1088 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>PES (10&#160;Hz)</td><td char="/" align="char">11/11</td><td char="/" align="char">2/6</td><td char="/" align="char">0/5</td><td char="/" align="char">4/6</td><td char="/" align="char">0/6</td><td>X</td></tr>
###xml 1097 1099 1088 1090 <td xmlns:xlink="http://www.w3.org/1999/xlink">BP</td>
###xml 1099 1104 1090 1095 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">11/11</td>
###xml 1104 1107 1095 1098 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">2/6</td>
###xml 1107 1110 1098 1101 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/5</td>
###xml 1110 1113 1101 1104 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">1/6</td>
###xml 1113 1116 1104 1107 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/6</td>
###xml 1116 1117 1107 1108 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1097 1117 1088 1108 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BP</td><td char="/" align="char">11/11</td><td char="/" align="char">2/6</td><td char="/" align="char">0/5</td><td char="/" align="char">1/6</td><td char="/" align="char">0/6</td><td>X</td></tr>
###xml 1040 1117 1031 1108 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>PES (8&#160;Hz)</td><td char="/" align="char">11/11</td><td char="/" align="char">4/6</td><td char="/" align="char">0/5</td><td char="/" align="char">5/6</td><td char="/" align="char">0/6</td><td>X</td></tr><tr><td>PES (10&#160;Hz)</td><td char="/" align="char">11/11</td><td char="/" align="char">2/6</td><td char="/" align="char">0/5</td><td char="/" align="char">4/6</td><td char="/" align="char">0/6</td><td>X</td></tr><tr><td>BP</td><td char="/" align="char">11/11</td><td char="/" align="char">2/6</td><td char="/" align="char">0/5</td><td char="/" align="char">1/6</td><td char="/" align="char">0/6</td><td>X</td></tr></tbody>
###xml 940 1117 935 1108 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th colspan="3">WT</th><th colspan="3">KPQ</th></tr><tr><th>Condition</th><th>Control</th><th>Flecainide 1&#160;&#956;M</th><th>Flecainide 3&#160;&#956;M</th><th>Control</th><th>Flecainide 1&#160;&#956;M</th><th>Flecainide 3&#160;&#956;M</th></tr></thead><tbody><tr><td>PES (8&#160;Hz)</td><td char="/" align="char">11/11</td><td char="/" align="char">4/6</td><td char="/" align="char">0/5</td><td char="/" align="char">5/6</td><td char="/" align="char">0/6</td><td>X</td></tr><tr><td>PES (10&#160;Hz)</td><td char="/" align="char">11/11</td><td char="/" align="char">2/6</td><td char="/" align="char">0/5</td><td char="/" align="char">4/6</td><td char="/" align="char">0/6</td><td>X</td></tr><tr><td>BP</td><td char="/" align="char">11/11</td><td char="/" align="char">2/6</td><td char="/" align="char">0/5</td><td char="/" align="char">1/6</td><td char="/" align="char">0/6</td><td>X</td></tr></tbody></table>
###xml 1117 1348 1108 1339 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Numbers of hearts in which one or more episodes of atrial arrhythmias occurred out of the total number of preparations studied under that condition (for example, 11/11 denotes that 11 hearts were arrhythmic out of 11 hearts tested)</p>
###xml 1348 1350 1339 1341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 1366 1371 1357 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 1380 1383 1367 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PES</italic>
###xml 1419 1421 1406 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BP</italic>
###xml 1436 1437 1423 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 1348 1568 1339 1554 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing, <italic>X</italic> failure of a consistent stimulus capture for the duration of each experiment in the presence of 3&#160;&#956;M flecainide for the KPQ group</p>
###xml 1117 1568 1108 1554 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Numbers of hearts in which one or more episodes of atrial arrhythmias occurred out of the total number of preparations studied under that condition (for example, 11/11 denotes that 11 hearts were arrhythmic out of 11 hearts tested)</p><p textid="42"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing, <italic>X</italic> failure of a consistent stimulus capture for the duration of each experiment in the presence of 3&#160;&#956;M flecainide for the KPQ group</p></table-wrap-foot>
###xml 805 1568 801 1554 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="40">Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of flecainide (1 and 3&#160;&#956;M)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th colspan="3">WT</th><th colspan="3">KPQ</th></tr><tr><th>Condition</th><th>Control</th><th>Flecainide 1&#160;&#956;M</th><th>Flecainide 3&#160;&#956;M</th><th>Control</th><th>Flecainide 1&#160;&#956;M</th><th>Flecainide 3&#160;&#956;M</th></tr></thead><tbody><tr><td>PES (8&#160;Hz)</td><td char="/" align="char">11/11</td><td char="/" align="char">4/6</td><td char="/" align="char">0/5</td><td char="/" align="char">5/6</td><td char="/" align="char">0/6</td><td>X</td></tr><tr><td>PES (10&#160;Hz)</td><td char="/" align="char">11/11</td><td char="/" align="char">2/6</td><td char="/" align="char">0/5</td><td char="/" align="char">4/6</td><td char="/" align="char">0/6</td><td>X</td></tr><tr><td>BP</td><td char="/" align="char">11/11</td><td char="/" align="char">2/6</td><td char="/" align="char">0/5</td><td char="/" align="char">1/6</td><td char="/" align="char">0/6</td><td>X</td></tr></tbody></table><table-wrap-foot><p textid="41">Numbers of hearts in which one or more episodes of atrial arrhythmias occurred out of the total number of preparations studied under that condition (for example, 11/11 denotes that 11 hearts were arrhythmic out of 11 hearts tested)</p><p textid="42"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing, <italic>X</italic> failure of a consistent stimulus capture for the duration of each experiment in the presence of 3&#160;&#956;M flecainide for the KPQ group</p></table-wrap-foot></table-wrap>
Table 2 summarises the number of hearts in each group that showed one or more arrhythmic episodes during any one of the adopted test procedures. It shows that in WT hearts, 1 muM flecainide exerted a significant reduction in arrhythmogenic incidence during PES conducted at a frequency of 10 Hz and during BP (P < 0.01 in both cases; Fisher's exact test); 3 muM flecainide produced significant effects through all the tests that were imposed (P < 0.001 for all three procedures). In KPQ hearts, 1 muM flecainide completely abolished arrhythmogenic phenomena through all the tests employed, with statistically significant effects obtained with PES conducted at an 8-Hz stimulation frequency (P < 0.05); 3 muM flecainide resulted in a loss of capture in the KPQ preparations which precluded detailed study. Table 2Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of flecainide (1 and 3 muM)GenotypeWTKPQConditionControlFlecainide 1 muMFlecainide 3 muMControlFlecainide 1 muMFlecainide 3 muMPES (8 Hz)11/114/60/55/60/6XPES (10 Hz)11/112/60/54/60/6XBP11/112/60/51/60/6XNumbers of hearts in which one or more episodes of atrial arrhythmias occurred out of the total number of preparations studied under that condition (for example, 11/11 denotes that 11 hearts were arrhythmic out of 11 hearts tested)WT wild-type, KPQ Scn5a+/Delta, PES programmed electrical stimulation, BP burst pacing, X failure of a consistent stimulus capture for the duration of each experiment in the presence of 3 muM flecainide for the KPQ group
###end p 39
###begin p 40
Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of flecainide (1 and 3 muM)
###end p 40
###begin p 41
Numbers of hearts in which one or more episodes of atrial arrhythmias occurred out of the total number of preparations studied under that condition (for example, 11/11 denotes that 11 hearts were arrhythmic out of 11 hearts tested)
###end p 41
###begin p 42
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 32 35 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PES</italic>
###xml 71 73 67 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BP</italic>
###xml 88 89 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
WT wild-type, KPQ Scn5a+/Delta, PES programmed electrical stimulation, BP burst pacing, X failure of a consistent stimulus capture for the duration of each experiment in the presence of 3 muM flecainide for the KPQ group
###end p 42
###begin p 43
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 13 14 13 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">overall</italic>
###xml 383 384 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 404 405 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 424 425 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 520 521 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 530 531 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 545 546 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 689 690 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 699 700 696 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 936 937 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 947 954 944 951 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 954 1074 951 1070 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of flecainide (1 and 3&#160;&#956;M)</p>
###xml 954 1074 951 1070 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of flecainide (1 and 3&#160;&#956;M)</p></caption>
###xml 1074 1083 1070 1079 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Procedure</th>
###xml 1083 1084 1079 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1083 1084 1079 1080 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"><italic>N</italic></th>
###xml 1084 1093 1080 1089 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Condition</th>
###xml 1093 1129 1089 1125 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Mean arrhythmic episode duration (s)</th>
###xml 1074 1129 1070 1125 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Procedure</th><th rowspan="2"><italic>N</italic></th><th rowspan="2">Condition</th><th colspan="5">Mean arrhythmic episode duration (s)</th></tr>
###xml 1129 1136 1125 1132 <th xmlns:xlink="http://www.w3.org/1999/xlink">Overall</th>
###xml 1136 1143 1132 1139 <th xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8211;1.0</th>
###xml 1143 1150 1139 1146 <th xmlns:xlink="http://www.w3.org/1999/xlink">1.1&#8211;5.0</th>
###xml 1150 1158 1146 1154 <th xmlns:xlink="http://www.w3.org/1999/xlink">5.1&#8211;10.0</th>
###xml 1158 1164 1154 1160 <th xmlns:xlink="http://www.w3.org/1999/xlink">10.0 +</th>
###xml 1129 1164 1125 1160 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Overall</th><th>0.2&#8211;1.0</th><th>1.1&#8211;5.0</th><th>5.1&#8211;10.0</th><th>10.0 +</th></tr>
###xml 1074 1164 1070 1160 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Procedure</th><th rowspan="2"><italic>N</italic></th><th rowspan="2">Condition</th><th colspan="5">Mean arrhythmic episode duration (s)</th></tr><tr><th>Overall</th><th>0.2&#8211;1.0</th><th>1.1&#8211;5.0</th><th>5.1&#8211;10.0</th><th>10.0 +</th></tr></thead>
###xml 1164 1166 1160 1162 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="8">WT</td>
###xml 1164 1166 1160 1162 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="8">WT</td></tr>
###xml 1166 1174 1162 1170 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">8&#160;Hz PES</td>
###xml 1174 1176 1170 1172 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 1176 1183 1172 1179 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 1183 1194 1179 1188 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.3&#8201;&#177;&#8201;1.1</td>
###xml 1194 1205 1188 1197 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.8&#8201;&#177;&#8201;1.0</td>
###xml 1205 1216 1197 1206 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.2</td>
###xml 1216 1219 1206 1209 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1219 1230 1209 1218 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.1</td>
###xml 1166 1230 1162 1218 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">8&#160;Hz PES</td><td char="." align="char">11</td><td>Control</td><td>4.3&#8201;&#177;&#8201;1.1</td><td>3.8&#8201;&#177;&#8201;1.0</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.2&#8201;&#177;&#8201;0.1</td></tr>
###xml 1230 1231 1218 1219 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1231 1247 1219 1234 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 1&#160;&#956;M</td>
###xml 1247 1258 1234 1243 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.2&#8201;&#177;&#8201;0.5</td>
###xml 1258 1270 1243 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.7&#8201;&#177;&#8201;0.3*</td>
###xml 1270 1281 1253 1262 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.5&#8201;&#177;&#8201;0.5</td>
###xml 1281 1284 1262 1265 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1284 1287 1265 1268 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1230 1287 1218 1268 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>1.2&#8201;&#177;&#8201;0.5</td><td>0.7&#8201;&#177;&#8201;0.3*</td><td>0.5&#8201;&#177;&#8201;0.5</td><td>0.0</td><td>0.0</td></tr>
###xml 1287 1288 1268 1269 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1288 1304 1269 1284 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 3&#160;&#956;M</td>
###xml 1304 1308 1284 1288 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0*</td>
###xml 1308 1312 1288 1292 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0*</td>
###xml 1312 1315 1292 1295 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1315 1318 1295 1298 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1318 1321 1298 1301 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1287 1321 1268 1301 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0*</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 1321 1330 1301 1310 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">10&#160;Hz PES</td>
###xml 1330 1332 1310 1312 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 1332 1339 1312 1319 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 1339 1350 1319 1328 <td xmlns:xlink="http://www.w3.org/1999/xlink">8.8&#8201;&#177;&#8201;1.0</td>
###xml 1350 1361 1328 1337 <td xmlns:xlink="http://www.w3.org/1999/xlink">8.1&#8201;&#177;&#8201;1.1</td>
###xml 1361 1372 1337 1346 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.5&#8201;&#177;&#8201;0.3</td>
###xml 1372 1383 1346 1355 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.1&#8201;&#177;&#8201;0.1</td>
###xml 1383 1394 1355 1364 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.1&#8201;&#177;&#8201;0.1</td>
###xml 1321 1394 1301 1364 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">10&#160;Hz PES</td><td char="." align="char">11</td><td>Control</td><td>8.8&#8201;&#177;&#8201;1.0</td><td>8.1&#8201;&#177;&#8201;1.1</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.1&#8201;&#177;&#8201;0.1</td><td>0.1&#8201;&#177;&#8201;0.1</td></tr>
###xml 1394 1395 1364 1365 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1395 1411 1365 1380 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 1&#160;&#956;M</td>
###xml 1411 1424 1380 1391 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.3&#8201;&#177;&#8201;1.5**</td>
###xml 1424 1437 1391 1402 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.5&#8201;&#177;&#8201;1.0**</td>
###xml 1437 1448 1402 1411 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.8&#8201;&#177;&#8201;0.8</td>
###xml 1448 1451 1411 1414 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1451 1454 1414 1417 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1394 1454 1364 1417 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>2.3&#8201;&#177;&#8201;1.5**</td><td>1.5&#8201;&#177;&#8201;1.0**</td><td>0.8&#8201;&#177;&#8201;0.8</td><td>0.0</td><td>0.0</td></tr>
###xml 1454 1455 1417 1418 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1455 1471 1418 1433 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 3&#160;&#956;M</td>
###xml 1471 1477 1433 1439 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0***</td>
###xml 1477 1483 1439 1445 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0***</td>
###xml 1483 1486 1445 1448 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1486 1489 1448 1451 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1489 1492 1451 1454 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1454 1492 1417 1454 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0***</td><td>0.0***</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 1492 1494 1454 1456 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">BP</td>
###xml 1494 1496 1456 1458 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 1496 1503 1458 1465 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 1503 1514 1465 1474 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.8&#8201;&#177;&#8201;0.8</td>
###xml 1514 1525 1474 1483 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.7&#8201;&#177;&#8201;1.0</td>
###xml 1525 1536 1483 1492 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.1</td>
###xml 1536 1547 1492 1501 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.4&#8201;&#177;&#8201;0.2</td>
###xml 1547 1558 1501 1510 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.5&#8201;&#177;&#8201;0.4</td>
###xml 1492 1558 1454 1510 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">BP</td><td char="." align="char">11</td><td>Control</td><td>3.8&#8201;&#177;&#8201;0.8</td><td>2.7&#8201;&#177;&#8201;1.0</td><td>0.3&#8201;&#177;&#8201;0.1</td><td>0.4&#8201;&#177;&#8201;0.2</td><td>0.5&#8201;&#177;&#8201;0.4</td></tr>
###xml 1558 1559 1510 1511 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1559 1575 1511 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 1&#160;&#956;M</td>
###xml 1575 1586 1526 1535 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.0&#8201;&#177;&#8201;0.8</td>
###xml 1586 1589 1535 1538 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1589 1600 1538 1547 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.8&#8201;&#177;&#8201;0.7</td>
###xml 1600 1611 1547 1556 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 1611 1614 1556 1559 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1558 1614 1510 1559 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>1.0&#8201;&#177;&#8201;0.8</td><td>0.0</td><td>0.8&#8201;&#177;&#8201;0.7</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td></tr>
###xml 1614 1615 1559 1560 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1615 1631 1560 1575 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 3&#160;&#956;M</td>
###xml 1631 1635 1575 1579 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0*</td>
###xml 1635 1638 1579 1582 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1638 1641 1582 1585 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1641 1644 1585 1588 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1644 1647 1588 1591 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1614 1647 1559 1591 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 1647 1650 1591 1594 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="8">KPQ</td>
###xml 1647 1650 1591 1594 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="8">KPQ</td></tr>
###xml 1650 1658 1594 1602 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">8&#160;Hz PES</td>
###xml 1658 1659 1602 1603 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1659 1666 1603 1610 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 1666 1677 1610 1619 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.5&#8201;&#177;&#8201;1.7</td>
###xml 1677 1689 1619 1629 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.0&#8201;&#177;&#8201;1.71</td>
###xml 1689 1700 1629 1638 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.5&#8201;&#177;&#8201;0.3</td>
###xml 1700 1703 1638 1641 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1703 1706 1641 1644 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1650 1706 1594 1644 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">8&#160;Hz PES</td><td char="." align="char">6</td><td>Control</td><td>4.5&#8201;&#177;&#8201;1.7</td><td>4.0&#8201;&#177;&#8201;1.71</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.0</td><td>0.0</td></tr>
###xml 1706 1707 1644 1645 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1707 1723 1645 1660 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 1&#160;&#956;M</td>
###xml 1723 1727 1660 1664 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0*</td>
###xml 1727 1731 1664 1668 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0*</td>
###xml 1731 1734 1668 1671 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1734 1737 1671 1674 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1737 1740 1674 1677 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1706 1740 1644 1677 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0*</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 1740 1741 1677 1678 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1741 1757 1678 1693 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 3&#160;&#956;M</td>
###xml 1757 1758 1693 1694 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1758 1759 1694 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1759 1760 1695 1696 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1760 1761 1696 1697 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1761 1762 1697 1698 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1740 1762 1677 1698 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr>
###xml 1762 1771 1698 1707 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">10&#160;Hz PES</td>
###xml 1771 1772 1707 1708 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1772 1779 1708 1715 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 1779 1790 1715 1724 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.8&#8201;&#177;&#8201;0.9</td>
###xml 1790 1801 1724 1733 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.0&#8201;&#177;&#8201;0.4</td>
###xml 1801 1812 1733 1742 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.8&#8201;&#177;&#8201;0.5</td>
###xml 1812 1815 1742 1745 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1815 1818 1745 1748 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1762 1818 1698 1748 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">10&#160;Hz PES</td><td char="." align="char">6</td><td>Control</td><td>1.8&#8201;&#177;&#8201;0.9</td><td>1.0&#8201;&#177;&#8201;0.4</td><td>0.8&#8201;&#177;&#8201;0.5</td><td>0.0</td><td>0.0</td></tr>
###xml 1818 1819 1748 1749 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1819 1835 1749 1764 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 1&#160;&#956;M</td>
###xml 1835 1838 1764 1767 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1838 1842 1767 1771 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0*</td>
###xml 1842 1845 1771 1774 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1845 1848 1774 1777 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1848 1851 1777 1780 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1818 1851 1748 1780 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 1851 1852 1780 1781 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1852 1868 1781 1796 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 3&#160;&#956;M</td>
###xml 1868 1869 1796 1797 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1869 1870 1797 1798 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1870 1871 1798 1799 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1871 1872 1799 1800 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1872 1873 1800 1801 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1851 1873 1780 1801 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr>
###xml 1873 1875 1801 1803 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">BP</td>
###xml 1875 1876 1803 1804 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1876 1883 1804 1811 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 1883 1894 1811 1820 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 1894 1905 1820 1829 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 1905 1908 1829 1832 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1908 1911 1832 1835 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1911 1914 1835 1838 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1873 1914 1801 1838 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">BP</td><td char="." align="char">6</td><td>Control</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 1914 1915 1838 1839 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1915 1931 1839 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 1&#160;&#956;M</td>
###xml 1931 1934 1854 1857 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1934 1937 1857 1860 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1937 1940 1860 1863 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1940 1943 1863 1866 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1943 1946 1866 1869 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 1914 1946 1838 1869 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 1946 1947 1869 1870 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1947 1963 1870 1885 <td xmlns:xlink="http://www.w3.org/1999/xlink">Flecainide 3&#160;&#956;M</td>
###xml 1963 1964 1885 1886 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1964 1965 1886 1887 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1965 1966 1887 1888 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1966 1967 1888 1889 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1967 1968 1889 1890 <td xmlns:xlink="http://www.w3.org/1999/xlink">X</td>
###xml 1946 1968 1869 1890 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr>
###xml 1164 1968 1160 1890 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="8">WT</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td char="." align="char">11</td><td>Control</td><td>4.3&#8201;&#177;&#8201;1.1</td><td>3.8&#8201;&#177;&#8201;1.0</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.2&#8201;&#177;&#8201;0.1</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>1.2&#8201;&#177;&#8201;0.5</td><td>0.7&#8201;&#177;&#8201;0.3*</td><td>0.5&#8201;&#177;&#8201;0.5</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0*</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td char="." align="char">11</td><td>Control</td><td>8.8&#8201;&#177;&#8201;1.0</td><td>8.1&#8201;&#177;&#8201;1.1</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.1&#8201;&#177;&#8201;0.1</td><td>0.1&#8201;&#177;&#8201;0.1</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>2.3&#8201;&#177;&#8201;1.5**</td><td>1.5&#8201;&#177;&#8201;1.0**</td><td>0.8&#8201;&#177;&#8201;0.8</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0***</td><td>0.0***</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">BP</td><td char="." align="char">11</td><td>Control</td><td>3.8&#8201;&#177;&#8201;0.8</td><td>2.7&#8201;&#177;&#8201;1.0</td><td>0.3&#8201;&#177;&#8201;0.1</td><td>0.4&#8201;&#177;&#8201;0.2</td><td>0.5&#8201;&#177;&#8201;0.4</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>1.0&#8201;&#177;&#8201;0.8</td><td>0.0</td><td>0.8&#8201;&#177;&#8201;0.7</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td></tr><tr><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td colspan="8">KPQ</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td char="." align="char">6</td><td>Control</td><td>4.5&#8201;&#177;&#8201;1.7</td><td>4.0&#8201;&#177;&#8201;1.71</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0*</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td char="." align="char">6</td><td>Control</td><td>1.8&#8201;&#177;&#8201;0.9</td><td>1.0&#8201;&#177;&#8201;0.4</td><td>0.8&#8201;&#177;&#8201;0.5</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="3">BP</td><td char="." align="char">6</td><td>Control</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr></tbody>
###xml 1074 1968 1070 1890 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Procedure</th><th rowspan="2"><italic>N</italic></th><th rowspan="2">Condition</th><th colspan="5">Mean arrhythmic episode duration (s)</th></tr><tr><th>Overall</th><th>0.2&#8211;1.0</th><th>1.1&#8211;5.0</th><th>5.1&#8211;10.0</th><th>10.0 +</th></tr></thead><tbody><tr><td colspan="8">WT</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td char="." align="char">11</td><td>Control</td><td>4.3&#8201;&#177;&#8201;1.1</td><td>3.8&#8201;&#177;&#8201;1.0</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.2&#8201;&#177;&#8201;0.1</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>1.2&#8201;&#177;&#8201;0.5</td><td>0.7&#8201;&#177;&#8201;0.3*</td><td>0.5&#8201;&#177;&#8201;0.5</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0*</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td char="." align="char">11</td><td>Control</td><td>8.8&#8201;&#177;&#8201;1.0</td><td>8.1&#8201;&#177;&#8201;1.1</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.1&#8201;&#177;&#8201;0.1</td><td>0.1&#8201;&#177;&#8201;0.1</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>2.3&#8201;&#177;&#8201;1.5**</td><td>1.5&#8201;&#177;&#8201;1.0**</td><td>0.8&#8201;&#177;&#8201;0.8</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0***</td><td>0.0***</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">BP</td><td char="." align="char">11</td><td>Control</td><td>3.8&#8201;&#177;&#8201;0.8</td><td>2.7&#8201;&#177;&#8201;1.0</td><td>0.3&#8201;&#177;&#8201;0.1</td><td>0.4&#8201;&#177;&#8201;0.2</td><td>0.5&#8201;&#177;&#8201;0.4</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>1.0&#8201;&#177;&#8201;0.8</td><td>0.0</td><td>0.8&#8201;&#177;&#8201;0.7</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td></tr><tr><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td colspan="8">KPQ</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td char="." align="char">6</td><td>Control</td><td>4.5&#8201;&#177;&#8201;1.7</td><td>4.0&#8201;&#177;&#8201;1.71</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0*</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td char="." align="char">6</td><td>Control</td><td>1.8&#8201;&#177;&#8201;0.9</td><td>1.0&#8201;&#177;&#8201;0.4</td><td>0.8&#8201;&#177;&#8201;0.5</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="3">BP</td><td char="." align="char">6</td><td>Control</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr></tbody></table>
###xml 1968 2372 1890 2294 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia durations under different conditions obtained during PES conducted at 8, 10&#160;Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and flecainide for WT (top panel) and KPQ (bottom panel) groups</p>
###xml 2372 2374 2294 2296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 2390 2395 2312 2317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 2404 2407 2322 2325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PES</italic>
###xml 2443 2445 2361 2363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BP</italic>
###xml 2460 2461 2378 2379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 2505 2506 2423 2424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 2372 2565 2294 2482 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing, <italic>N</italic> Numbers of hearts used for each condition, <italic>X</italic> loss of capture with 3&#160;&#956;M flecainide for KPQ preparations</p>
###xml 2566 2567 2483 2484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2578 2579 2495 2496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2592 2593 2509 2510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2565 2602 2482 2519 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">*<italic>P</italic>&#8201;&lt;&#8201;0.05, **<italic>P</italic>&#8201;&lt;&#8201;0.005, ***<italic>P</italic>&#8201;&lt;&#8201;0.0005</p>
###xml 1968 2602 1890 2519 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia durations under different conditions obtained during PES conducted at 8, 10&#160;Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and flecainide for WT (top panel) and KPQ (bottom panel) groups</p><p textid="46"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing, <italic>N</italic> Numbers of hearts used for each condition, <italic>X</italic> loss of capture with 3&#160;&#956;M flecainide for KPQ preparations</p><p textid="47">*<italic>P</italic>&#8201;&lt;&#8201;0.05, **<italic>P</italic>&#8201;&lt;&#8201;0.005, ***<italic>P</italic>&#8201;&lt;&#8201;0.0005</p></table-wrap-foot>
###xml 947 2602 944 2519 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="44">Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of flecainide (1 and 3&#160;&#956;M)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Procedure</th><th rowspan="2"><italic>N</italic></th><th rowspan="2">Condition</th><th colspan="5">Mean arrhythmic episode duration (s)</th></tr><tr><th>Overall</th><th>0.2&#8211;1.0</th><th>1.1&#8211;5.0</th><th>5.1&#8211;10.0</th><th>10.0 +</th></tr></thead><tbody><tr><td colspan="8">WT</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td char="." align="char">11</td><td>Control</td><td>4.3&#8201;&#177;&#8201;1.1</td><td>3.8&#8201;&#177;&#8201;1.0</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.2&#8201;&#177;&#8201;0.1</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>1.2&#8201;&#177;&#8201;0.5</td><td>0.7&#8201;&#177;&#8201;0.3*</td><td>0.5&#8201;&#177;&#8201;0.5</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0*</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td char="." align="char">11</td><td>Control</td><td>8.8&#8201;&#177;&#8201;1.0</td><td>8.1&#8201;&#177;&#8201;1.1</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.1&#8201;&#177;&#8201;0.1</td><td>0.1&#8201;&#177;&#8201;0.1</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>2.3&#8201;&#177;&#8201;1.5**</td><td>1.5&#8201;&#177;&#8201;1.0**</td><td>0.8&#8201;&#177;&#8201;0.8</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0***</td><td>0.0***</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">BP</td><td char="." align="char">11</td><td>Control</td><td>3.8&#8201;&#177;&#8201;0.8</td><td>2.7&#8201;&#177;&#8201;1.0</td><td>0.3&#8201;&#177;&#8201;0.1</td><td>0.4&#8201;&#177;&#8201;0.2</td><td>0.5&#8201;&#177;&#8201;0.4</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>1.0&#8201;&#177;&#8201;0.8</td><td>0.0</td><td>0.8&#8201;&#177;&#8201;0.7</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td></tr><tr><td char="." align="char">5</td><td>Flecainide 3&#160;&#956;M</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td colspan="8">KPQ</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td char="." align="char">6</td><td>Control</td><td>4.5&#8201;&#177;&#8201;1.7</td><td>4.0&#8201;&#177;&#8201;1.71</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0*</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td char="." align="char">6</td><td>Control</td><td>1.8&#8201;&#177;&#8201;0.9</td><td>1.0&#8201;&#177;&#8201;0.4</td><td>0.8&#8201;&#177;&#8201;0.5</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="3">BP</td><td char="." align="char">6</td><td>Control</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td char="." align="char">6</td><td>Flecainide 3&#160;&#956;M</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr></tbody></table><table-wrap-foot><p textid="45">Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia durations under different conditions obtained during PES conducted at 8, 10&#160;Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and flecainide for WT (top panel) and KPQ (bottom panel) groups</p><p textid="46"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing, <italic>N</italic> Numbers of hearts used for each condition, <italic>X</italic> loss of capture with 3&#160;&#956;M flecainide for KPQ preparations</p><p textid="47">*<italic>P</italic>&#8201;&lt;&#8201;0.05, **<italic>P</italic>&#8201;&lt;&#8201;0.005, ***<italic>P</italic>&#8201;&lt;&#8201;0.0005</p></table-wrap-foot></table-wrap>
###xml 2602 2609 2519 2526 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 2609 2728 2526 2644 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of quinidine (1 and 3&#160;&#956;M)</p>
###xml 2609 2728 2526 2644 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of quinidine (1 and 3&#160;&#956;M)</p></caption>
###xml 2728 2737 2644 2653 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Procedure</th>
###xml 2737 2738 2653 2654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 2737 2738 2653 2654 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"><italic>N</italic></th>
###xml 2738 2747 2654 2663 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Condition</th>
###xml 2747 2783 2663 2699 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Mean arrhythmic episode duration (s)</th>
###xml 2728 2783 2644 2699 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Procedure</th><th rowspan="2"><italic>N</italic></th><th rowspan="2">Condition</th><th colspan="5">Mean arrhythmic episode duration (s)</th></tr>
###xml 2783 2790 2699 2706 <th xmlns:xlink="http://www.w3.org/1999/xlink">Overall</th>
###xml 2790 2797 2706 2713 <th xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8211;1.0</th>
###xml 2797 2804 2713 2720 <th xmlns:xlink="http://www.w3.org/1999/xlink">1.1&#8211;5.0</th>
###xml 2804 2812 2720 2728 <th xmlns:xlink="http://www.w3.org/1999/xlink">5.1&#8211;10.0</th>
###xml 2812 2818 2728 2734 <th xmlns:xlink="http://www.w3.org/1999/xlink">10.0 +</th>
###xml 2783 2818 2699 2734 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Overall</th><th>0.2&#8211;1.0</th><th>1.1&#8211;5.0</th><th>5.1&#8211;10.0</th><th>10.0 +</th></tr>
###xml 2728 2818 2644 2734 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Procedure</th><th rowspan="2"><italic>N</italic></th><th rowspan="2">Condition</th><th colspan="5">Mean arrhythmic episode duration (s)</th></tr><tr><th>Overall</th><th>0.2&#8211;1.0</th><th>1.1&#8211;5.0</th><th>5.1&#8211;10.0</th><th>10.0 +</th></tr></thead>
###xml 2818 2820 2734 2736 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="8">WT</td>
###xml 2818 2820 2734 2736 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="8">WT</td></tr>
###xml 2820 2828 2736 2744 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">8&#160;Hz PES</td>
###xml 2828 2829 2744 2745 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 2829 2836 2745 2752 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 2836 2847 2752 2761 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.8&#8201;&#177;&#8201;1.9</td>
###xml 2847 2858 2761 2770 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.3&#8201;&#177;&#8201;1.9</td>
###xml 2858 2869 2770 2779 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.8&#8201;&#177;&#8201;0.4</td>
###xml 2869 2880 2779 2788 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 2880 2891 2788 2797 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.5&#8201;&#177;&#8201;0.3</td>
###xml 2820 2891 2736 2797 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">8&#160;Hz PES</td><td>6</td><td>Control</td><td>6.8&#8201;&#177;&#8201;1.9</td><td>5.3&#8201;&#177;&#8201;1.9</td><td>0.8&#8201;&#177;&#8201;0.4</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.5&#8201;&#177;&#8201;0.3</td></tr>
###xml 2891 2892 2797 2798 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 2892 2907 2798 2812 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 1&#160;&#956;M</td>
###xml 2907 2918 2812 2821 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.0&#8201;&#177;&#8201;0.6</td>
###xml 2918 2929 2821 2830 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.7&#8201;&#177;&#8201;0.4</td>
###xml 2929 2940 2830 2839 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.3</td>
###xml 2940 2951 2839 2848 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.8&#8201;&#177;&#8201;0.4</td>
###xml 2951 2962 2848 2857 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 2891 2962 2797 2857 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>4.0&#8201;&#177;&#8201;0.6</td><td>2.7&#8201;&#177;&#8201;0.4</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.8&#8201;&#177;&#8201;0.4</td><td>0.2&#8201;&#177;&#8201;0.2</td></tr>
###xml 2962 2963 2857 2858 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 2963 2978 2858 2872 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 3&#160;&#956;M</td>
###xml 2978 2990 2872 2882 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.2*</td>
###xml 2990 3002 2882 2892 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.2*</td>
###xml 3002 3005 2892 2895 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3005 3008 2895 2898 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3008 3012 2898 2902 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.00</td>
###xml 2962 3012 2857 2902 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.3&#8201;&#177;&#8201;0.2*</td><td>0.3&#8201;&#177;&#8201;0.2*</td><td>0.0</td><td>0.0</td><td>0.00</td></tr>
###xml 3012 3021 2902 2911 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">10&#160;Hz PES</td>
###xml 3021 3022 2911 2912 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 3022 3029 2912 2919 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 3029 3040 2919 2928 <td xmlns:xlink="http://www.w3.org/1999/xlink">9.7&#8201;&#177;&#8201;0.7</td>
###xml 3040 3051 2928 2937 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.3&#8201;&#177;&#8201;1.5</td>
###xml 3051 3062 2937 2946 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.3&#8201;&#177;&#8201;0.8</td>
###xml 3062 3073 2946 2955 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.3</td>
###xml 3073 3084 2955 2964 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.7&#8201;&#177;&#8201;0.5</td>
###xml 3012 3084 2902 2964 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">10&#160;Hz PES</td><td>6</td><td>Control</td><td>9.7&#8201;&#177;&#8201;0.7</td><td>7.3&#8201;&#177;&#8201;1.5</td><td>1.3&#8201;&#177;&#8201;0.8</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.7&#8201;&#177;&#8201;0.5</td></tr>
###xml 3084 3085 2964 2965 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 3085 3100 2965 2979 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 1&#160;&#956;M</td>
###xml 3100 3112 2979 2989 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.5&#8201;&#177;&#8201;1.6*</td>
###xml 3112 3123 2989 2998 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.7&#8201;&#177;&#8201;1.2</td>
###xml 3123 3134 2998 3007 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.3</td>
###xml 3134 3145 3007 3016 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.5&#8201;&#177;&#8201;0.3</td>
###xml 3145 3149 3016 3020 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.00</td>
###xml 3084 3149 2964 3020 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>4.5&#8201;&#177;&#8201;1.6*</td><td>3.7&#8201;&#177;&#8201;1.2</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.00</td></tr>
###xml 3149 3150 3020 3021 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 3150 3165 3021 3035 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 3&#160;&#956;M</td>
###xml 3165 3171 3035 3041 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0***</td>
###xml 3171 3176 3041 3046 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0**</td>
###xml 3176 3179 3046 3049 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3179 3182 3049 3052 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3182 3186 3052 3056 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.00</td>
###xml 3149 3186 3020 3056 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.0***</td><td>0.0**</td><td>0.0</td><td>0.0</td><td>0.00</td></tr>
###xml 3186 3188 3056 3058 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">BP</td>
###xml 3188 3189 3058 3059 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 3189 3196 3059 3066 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 3196 3207 3066 3075 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.8&#8201;&#177;&#8201;0.3</td>
###xml 3207 3218 3075 3084 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.2</td>
###xml 3218 3229 3084 3093 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 3229 3240 3093 3102 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 3240 3251 3102 3111 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 3186 3251 3056 3111 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">BP</td><td>6</td><td>Control</td><td>0.8&#8201;&#177;&#8201;0.3</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td></tr>
###xml 3251 3252 3111 3112 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 3252 3267 3112 3126 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 1&#160;&#956;M</td>
###xml 3267 3278 3126 3135 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.5&#8201;&#177;&#8201;0.2</td>
###xml 3278 3289 3135 3144 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.2</td>
###xml 3289 3292 3144 3147 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3292 3303 3147 3156 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 3303 3306 3156 3159 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3251 3306 3111 3159 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>0.5&#8201;&#177;&#8201;0.2</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td></tr>
###xml 3306 3307 3159 3160 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 3307 3322 3160 3174 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 3&#160;&#956;M</td>
###xml 3322 3326 3174 3178 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0*</td>
###xml 3326 3329 3178 3181 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3329 3332 3181 3184 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3332 3335 3184 3187 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3335 3338 3187 3190 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3306 3338 3159 3190 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 3338 3341 3190 3193 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="8">KPQ</td>
###xml 3338 3341 3190 3193 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="8">KPQ</td></tr>
###xml 3341 3349 3193 3201 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">8&#160;Hz PES</td>
###xml 3349 3351 3201 3203 <td xmlns:xlink="http://www.w3.org/1999/xlink">10</td>
###xml 3351 3358 3203 3210 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 3358 3369 3210 3219 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.3&#8201;&#177;&#8201;0.2</td>
###xml 3369 3380 3219 3228 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2&#8201;&#177;&#8201;0.2</td>
###xml 3380 3391 3228 3237 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.1&#8201;&#177;&#8201;0.1</td>
###xml 3391 3394 3237 3240 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3394 3397 3240 3243 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3341 3397 3193 3243 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">8&#160;Hz PES</td><td>10</td><td>Control</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.1&#8201;&#177;&#8201;0.1</td><td>0.0</td><td>0.0</td></tr>
###xml 3397 3398 3243 3244 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 3398 3413 3244 3258 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 1&#160;&#956;M</td>
###xml 3413 3416 3258 3261 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.0</td>
###xml 3416 3419 3261 3264 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.0</td>
###xml 3419 3422 3264 3267 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3422 3425 3267 3270 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3425 3428 3270 3273 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3397 3428 3243 3273 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>1.0</td><td>1.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 3428 3429 3273 3274 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 3429 3444 3274 3288 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 3&#160;&#956;M</td>
###xml 3444 3447 3288 3291 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3447 3450 3291 3294 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3450 3453 3294 3297 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3453 3456 3297 3300 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3456 3459 3300 3303 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3428 3459 3273 3303 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 3459 3468 3303 3312 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">10&#160;Hz PES</td>
###xml 3468 3470 3312 3314 <td xmlns:xlink="http://www.w3.org/1999/xlink">10</td>
###xml 3470 3477 3314 3321 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 3477 3488 3321 3330 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.6&#8201;&#177;&#8201;0.4</td>
###xml 3488 3499 3330 3339 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.6&#8201;&#177;&#8201;0.4</td>
###xml 3499 3502 3339 3342 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3502 3505 3342 3345 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3505 3508 3345 3348 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3459 3508 3303 3348 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">10&#160;Hz PES</td><td>10</td><td>Control</td><td>0.6&#8201;&#177;&#8201;0.4</td><td>0.6&#8201;&#177;&#8201;0.4</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 3508 3509 3348 3349 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 3509 3524 3349 3363 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 1&#160;&#956;M</td>
###xml 3524 3527 3363 3366 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3527 3530 3366 3369 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3530 3533 3369 3372 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3533 3536 3372 3375 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3536 3539 3375 3378 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3508 3539 3348 3378 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 3539 3540 3378 3379 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 3540 3555 3379 3393 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 3&#160;&#956;M</td>
###xml 3555 3558 3393 3396 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3558 3561 3396 3399 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3561 3564 3399 3402 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3564 3567 3402 3405 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3567 3570 3405 3408 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3539 3570 3378 3408 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 3570 3572 3408 3410 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">BP</td>
###xml 3572 3574 3410 3412 <td xmlns:xlink="http://www.w3.org/1999/xlink">10</td>
###xml 3574 3581 3412 3419 <td xmlns:xlink="http://www.w3.org/1999/xlink">Control</td>
###xml 3581 3584 3419 3422 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3584 3587 3422 3425 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3587 3590 3425 3428 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3590 3593 3428 3431 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3593 3596 3431 3434 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3570 3596 3408 3434 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="3">BP</td><td>10</td><td>Control</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 3596 3597 3434 3435 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 3597 3612 3435 3449 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 1&#160;&#956;M</td>
###xml 3612 3615 3449 3452 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3615 3618 3452 3455 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3618 3621 3455 3458 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3621 3624 3458 3461 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3624 3627 3461 3464 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3596 3627 3434 3464 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 3627 3628 3464 3465 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 3628 3643 3465 3479 <td xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 3&#160;&#956;M</td>
###xml 3643 3646 3479 3482 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3646 3649 3482 3485 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3649 3652 3485 3488 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3652 3655 3488 3491 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3655 3658 3491 3494 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.0</td>
###xml 3627 3658 3464 3494 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr>
###xml 2818 3658 2734 3494 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="8">WT</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td>6</td><td>Control</td><td>6.8&#8201;&#177;&#8201;1.9</td><td>5.3&#8201;&#177;&#8201;1.9</td><td>0.8&#8201;&#177;&#8201;0.4</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.5&#8201;&#177;&#8201;0.3</td></tr><tr><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>4.0&#8201;&#177;&#8201;0.6</td><td>2.7&#8201;&#177;&#8201;0.4</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.8&#8201;&#177;&#8201;0.4</td><td>0.2&#8201;&#177;&#8201;0.2</td></tr><tr><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.3&#8201;&#177;&#8201;0.2*</td><td>0.3&#8201;&#177;&#8201;0.2*</td><td>0.0</td><td>0.0</td><td>0.00</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td>6</td><td>Control</td><td>9.7&#8201;&#177;&#8201;0.7</td><td>7.3&#8201;&#177;&#8201;1.5</td><td>1.3&#8201;&#177;&#8201;0.8</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.7&#8201;&#177;&#8201;0.5</td></tr><tr><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>4.5&#8201;&#177;&#8201;1.6*</td><td>3.7&#8201;&#177;&#8201;1.2</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.00</td></tr><tr><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.0***</td><td>0.0**</td><td>0.0</td><td>0.0</td><td>0.00</td></tr><tr><td rowspan="3">BP</td><td>6</td><td>Control</td><td>0.8&#8201;&#177;&#8201;0.3</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td></tr><tr><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>0.5&#8201;&#177;&#8201;0.2</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td></tr><tr><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td colspan="8">KPQ</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td>10</td><td>Control</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.1&#8201;&#177;&#8201;0.1</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>1.0</td><td>1.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td>10</td><td>Control</td><td>0.6&#8201;&#177;&#8201;0.4</td><td>0.6&#8201;&#177;&#8201;0.4</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">BP</td><td>10</td><td>Control</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr></tbody>
###xml 2728 3658 2644 3494 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Procedure</th><th rowspan="2"><italic>N</italic></th><th rowspan="2">Condition</th><th colspan="5">Mean arrhythmic episode duration (s)</th></tr><tr><th>Overall</th><th>0.2&#8211;1.0</th><th>1.1&#8211;5.0</th><th>5.1&#8211;10.0</th><th>10.0 +</th></tr></thead><tbody><tr><td colspan="8">WT</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td>6</td><td>Control</td><td>6.8&#8201;&#177;&#8201;1.9</td><td>5.3&#8201;&#177;&#8201;1.9</td><td>0.8&#8201;&#177;&#8201;0.4</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.5&#8201;&#177;&#8201;0.3</td></tr><tr><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>4.0&#8201;&#177;&#8201;0.6</td><td>2.7&#8201;&#177;&#8201;0.4</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.8&#8201;&#177;&#8201;0.4</td><td>0.2&#8201;&#177;&#8201;0.2</td></tr><tr><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.3&#8201;&#177;&#8201;0.2*</td><td>0.3&#8201;&#177;&#8201;0.2*</td><td>0.0</td><td>0.0</td><td>0.00</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td>6</td><td>Control</td><td>9.7&#8201;&#177;&#8201;0.7</td><td>7.3&#8201;&#177;&#8201;1.5</td><td>1.3&#8201;&#177;&#8201;0.8</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.7&#8201;&#177;&#8201;0.5</td></tr><tr><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>4.5&#8201;&#177;&#8201;1.6*</td><td>3.7&#8201;&#177;&#8201;1.2</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.00</td></tr><tr><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.0***</td><td>0.0**</td><td>0.0</td><td>0.0</td><td>0.00</td></tr><tr><td rowspan="3">BP</td><td>6</td><td>Control</td><td>0.8&#8201;&#177;&#8201;0.3</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td></tr><tr><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>0.5&#8201;&#177;&#8201;0.2</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td></tr><tr><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td colspan="8">KPQ</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td>10</td><td>Control</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.1&#8201;&#177;&#8201;0.1</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>1.0</td><td>1.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td>10</td><td>Control</td><td>0.6&#8201;&#177;&#8201;0.4</td><td>0.6&#8201;&#177;&#8201;0.4</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">BP</td><td>10</td><td>Control</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr></tbody></table>
###xml 3658 4069 3494 3905 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49">Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia (AA) durations under different conditions obtained during PES conducted at 8 Hz, 10&#160;Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and quinidine for WT (top panel) and KPQ (bottom panel) groups</p>
###xml 4069 4071 3905 3907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 4087 4092 3923 3928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 4101 4104 3933 3936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PES</italic>
###xml 4140 4142 3972 3974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BP</italic>
###xml 4157 4158 3989 3990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 4069 4200 3905 4032 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing, <italic>N</italic> Numbers of hearts used for each condition</p>
###xml 4201 4202 4033 4034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 4213 4214 4045 4046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 4227 4228 4059 4060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 4200 4237 4032 4069 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">*<italic>P</italic>&#8201;&lt;&#8201;0.05, **<italic>P</italic>&#8201;&lt;&#8201;0.005, ***<italic>P</italic>&#8201;&lt;&#8201;0.0005</p>
###xml 3658 4237 3494 4069 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49">Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia (AA) durations under different conditions obtained during PES conducted at 8 Hz, 10&#160;Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and quinidine for WT (top panel) and KPQ (bottom panel) groups</p><p textid="50"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing, <italic>N</italic> Numbers of hearts used for each condition</p><p textid="51">*<italic>P</italic>&#8201;&lt;&#8201;0.05, **<italic>P</italic>&#8201;&lt;&#8201;0.005, ***<italic>P</italic>&#8201;&lt;&#8201;0.0005</p></table-wrap-foot>
###xml 2602 4237 2519 4069 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="48">Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of quinidine (1 and 3&#160;&#956;M)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Procedure</th><th rowspan="2"><italic>N</italic></th><th rowspan="2">Condition</th><th colspan="5">Mean arrhythmic episode duration (s)</th></tr><tr><th>Overall</th><th>0.2&#8211;1.0</th><th>1.1&#8211;5.0</th><th>5.1&#8211;10.0</th><th>10.0 +</th></tr></thead><tbody><tr><td colspan="8">WT</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td>6</td><td>Control</td><td>6.8&#8201;&#177;&#8201;1.9</td><td>5.3&#8201;&#177;&#8201;1.9</td><td>0.8&#8201;&#177;&#8201;0.4</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.5&#8201;&#177;&#8201;0.3</td></tr><tr><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>4.0&#8201;&#177;&#8201;0.6</td><td>2.7&#8201;&#177;&#8201;0.4</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.8&#8201;&#177;&#8201;0.4</td><td>0.2&#8201;&#177;&#8201;0.2</td></tr><tr><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.3&#8201;&#177;&#8201;0.2*</td><td>0.3&#8201;&#177;&#8201;0.2*</td><td>0.0</td><td>0.0</td><td>0.00</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td>6</td><td>Control</td><td>9.7&#8201;&#177;&#8201;0.7</td><td>7.3&#8201;&#177;&#8201;1.5</td><td>1.3&#8201;&#177;&#8201;0.8</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.7&#8201;&#177;&#8201;0.5</td></tr><tr><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>4.5&#8201;&#177;&#8201;1.6*</td><td>3.7&#8201;&#177;&#8201;1.2</td><td>0.3&#8201;&#177;&#8201;0.3</td><td>0.5&#8201;&#177;&#8201;0.3</td><td>0.00</td></tr><tr><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.0***</td><td>0.0**</td><td>0.0</td><td>0.0</td><td>0.00</td></tr><tr><td rowspan="3">BP</td><td>6</td><td>Control</td><td>0.8&#8201;&#177;&#8201;0.3</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td></tr><tr><td>6</td><td>Quinidine 1&#160;&#956;M</td><td>0.5&#8201;&#177;&#8201;0.2</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.0</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.0</td></tr><tr><td>6</td><td>Quinidine 3&#160;&#956;M</td><td>0.0*</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td colspan="8">KPQ</td></tr><tr><td rowspan="3">8&#160;Hz PES</td><td>10</td><td>Control</td><td>0.3&#8201;&#177;&#8201;0.2</td><td>0.2&#8201;&#177;&#8201;0.2</td><td>0.1&#8201;&#177;&#8201;0.1</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>1.0</td><td>1.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">10&#160;Hz PES</td><td>10</td><td>Control</td><td>0.6&#8201;&#177;&#8201;0.4</td><td>0.6&#8201;&#177;&#8201;0.4</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td rowspan="3">BP</td><td>10</td><td>Control</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 1&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>5</td><td>Quinidine 3&#160;&#956;M</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr></tbody></table><table-wrap-foot><p textid="49">Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia (AA) durations under different conditions obtained during PES conducted at 8 Hz, 10&#160;Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and quinidine for WT (top panel) and KPQ (bottom panel) groups</p><p textid="50"><italic>WT</italic> wild-type, KPQ <italic>Scn5a</italic>+/&#916;, <italic>PES</italic> programmed electrical stimulation, <italic>BP</italic> burst pacing, <italic>N</italic> Numbers of hearts used for each condition</p><p textid="51">*<italic>P</italic>&#8201;&lt;&#8201;0.05, **<italic>P</italic>&#8201;&lt;&#8201;0.005, ***<italic>P</italic>&#8201;&lt;&#8201;0.0005</p></table-wrap-foot></table-wrap>
Tables 3 and 4 summarise the effects of flecainide and quinidine, respectively, on mean overall incidences of atrial arrhythmic episodes per heart through the WT or KPQ hearts that were studied. In the WT preparations, flecainide (1 muM) reduced the average total incidences of arrhythmic episodes per heart whether these were undergoing PES at stimulation frequencies of both 8 Hz (P = 0.07) and 10 Hz (P = 0.002), and BP (P = 0.05) and higher (3 muM) concentrations completely abolished all such arrhythmic phenomena (P = 0.03, P < 0.0001 and P = 0.01, respectively). KPQ preparations required lower (1 muM) flecainide concentrations to achieve such a complete abolition of arrhythmias (P = 0.02, P = 0.06) with PES at 8 and 10 Hz; the BP protocol resulted in low mean total incidences of atrial arrhythmic episodes per heart in both control and treated groups, and this accounts for the lack of significance between the two results (P = 0.34). Table 3Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of flecainide (1 and 3 muM)ProcedureNConditionMean arrhythmic episode duration (s)Overall0.2-1.01.1-5.05.1-10.010.0 +WT8 Hz PES11Control4.3 +/- 1.13.8 +/- 1.00.3 +/- 0.20.00.2 +/- 0.16Flecainide 1 muM1.2 +/- 0.50.7 +/- 0.3*0.5 +/- 0.50.00.05Flecainide 3 muM0.0*0.0*0.00.00.010 Hz PES11Control8.8 +/- 1.08.1 +/- 1.10.5 +/- 0.30.1 +/- 0.10.1 +/- 0.16Flecainide 1 muM2.3 +/- 1.5**1.5 +/- 1.0**0.8 +/- 0.80.00.05Flecainide 3 muM0.0***0.0***0.00.00.0BP11Control3.8 +/- 0.82.7 +/- 1.00.3 +/- 0.10.4 +/- 0.20.5 +/- 0.46Flecainide 1 muM1.0 +/- 0.80.00.8 +/- 0.70.2 +/- 0.20.05Flecainide 3 muM0.0*0.00.00.00.0KPQ8 Hz PES6Control4.5 +/- 1.74.0 +/- 1.710.5 +/- 0.30.00.06Flecainide 1 muM0.0*0.0*0.00.00.06Flecainide 3 muMXXXXX10 Hz PES6Control1.8 +/- 0.91.0 +/- 0.40.8 +/- 0.50.00.06Flecainide 1 muM0.00.0*0.00.00.06Flecainide 3 muMXXXXXBP6Control0.2 +/- 0.20.2 +/- 0.20.00.00.06Flecainide 1 muM0.00.00.00.00.06Flecainide 3 muMXXXXXMean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia durations under different conditions obtained during PES conducted at 8, 10 Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and flecainide for WT (top panel) and KPQ (bottom panel) groupsWT wild-type, KPQ Scn5a+/Delta, PES programmed electrical stimulation, BP burst pacing, N Numbers of hearts used for each condition, X loss of capture with 3 muM flecainide for KPQ preparations*P < 0.05, **P < 0.005, ***P < 0.0005Table 4Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of quinidine (1 and 3 muM)ProcedureNConditionMean arrhythmic episode duration (s)Overall0.2-1.01.1-5.05.1-10.010.0 +WT8 Hz PES6Control6.8 +/- 1.95.3 +/- 1.90.8 +/- 0.40.2 +/- 0.20.5 +/- 0.36Quinidine 1 muM4.0 +/- 0.62.7 +/- 0.40.3 +/- 0.30.8 +/- 0.40.2 +/- 0.26Quinidine 3 muM0.3 +/- 0.2*0.3 +/- 0.2*0.00.00.0010 Hz PES6Control9.7 +/- 0.77.3 +/- 1.51.3 +/- 0.80.3 +/- 0.30.7 +/- 0.56Quinidine 1 muM4.5 +/- 1.6*3.7 +/- 1.20.3 +/- 0.30.5 +/- 0.30.006Quinidine 3 muM0.0***0.0**0.00.00.00BP6Control0.8 +/- 0.30.3 +/- 0.20.2 +/- 0.20.2 +/- 0.20.2 +/- 0.26Quinidine 1 muM0.5 +/- 0.20.3 +/- 0.20.00.2 +/- 0.20.06Quinidine 3 muM0.0*0.00.00.00.0KPQ8 Hz PES10Control0.3 +/- 0.20.2 +/- 0.20.1 +/- 0.10.00.05Quinidine 1 muM1.01.00.00.00.05Quinidine 3 muM0.00.00.00.00.010 Hz PES10Control0.6 +/- 0.40.6 +/- 0.40.00.00.05Quinidine 1 muM0.00.00.00.00.05Quinidine 3 muM0.00.00.00.00.0BP10Control0.00.00.00.00.05Quinidine 1 muM0.00.00.00.00.05Quinidine 3 muM0.00.00.00.00.0Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia (AA) durations under different conditions obtained during PES conducted at 8 Hz, 10 Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and quinidine for WT (top panel) and KPQ (bottom panel) groupsWT wild-type, KPQ Scn5a+/Delta, PES programmed electrical stimulation, BP burst pacing, N Numbers of hearts used for each condition*P < 0.05, **P < 0.005, ***P < 0.0005
###end p 43
###begin p 44
Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of flecainide (1 and 3 muM)
###end p 44
###begin p 45
Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia durations under different conditions obtained during PES conducted at 8, 10 Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and flecainide for WT (top panel) and KPQ (bottom panel) groups
###end p 45
###begin p 46
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 32 35 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PES</italic>
###xml 71 73 67 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BP</italic>
###xml 88 89 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 133 134 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
WT wild-type, KPQ Scn5a+/Delta, PES programmed electrical stimulation, BP burst pacing, N Numbers of hearts used for each condition, X loss of capture with 3 muM flecainide for KPQ preparations
###end p 46
###begin p 47
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 27 28 27 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
*P < 0.05, **P < 0.005, ***P < 0.0005
###end p 47
###begin p 48
Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of quinidine (1 and 3 muM)
###end p 48
###begin p 49
Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia (AA) durations under different conditions obtained during PES conducted at 8 Hz, 10 Hz and BP. The results of one-way ANOVA for correlated samples are shown and compare arrhythmogenic incidences between control and quinidine for WT (top panel) and KPQ (bottom panel) groups
###end p 49
###begin p 50
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 32 35 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PES</italic>
###xml 71 73 67 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BP</italic>
###xml 88 89 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
WT wild-type, KPQ Scn5a+/Delta, PES programmed electrical stimulation, BP burst pacing, N Numbers of hearts used for each condition
###end p 50
###begin p 51
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 27 28 27 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
*P < 0.05, **P < 0.005, ***P < 0.0005
###end p 51
###begin p 52
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 237 252 236 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mean incidences</italic>
###xml 359 360 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 372 373 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 406 407 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 420 421 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 655 656 648 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 676 677 669 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Table 3 also provides a summary of the effects of flecainide on the breakdown of arrhythmic episodes sorted by the four arrhythmic durations introduced above. In WT hearts, flecainide whether applied at 1 or 3 muM, significantly reduced mean incidences of arrhythmic episodes lasting </=1.0 s, during PES whether conducted at stimulation frequencies of 8 Hz (P = 0.03 and P = 0.02, respectively) or 10 Hz (P = 0.002 and P = 0.0003, respectively). In the KPQ group, flecainide similarly reduced the incidence of such episodes lasting </=1.0 s: 1 muM rather than 3 muM flecainide sufficed to abolish all atrial arrhytmias whether PES was conducted at 8 Hz (P = 0.04) and 10 Hz (P = 0.02) stimulation frequencies.
###end p 52
###begin p 53
BP resulted in relatively low incidences of arrhythmic episodes per heart in both WT and KPQ whether in the presence or the absence of flecainide; the only one out of six hearts that displayed a short (0.24 s) atrial arrhythmic episode failed to show any with 1 muM flecainide.
###end p 53
###begin p 54
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab5" ref-type="table">5</xref>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 266 267 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 531 532 529 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 962 969 959 966 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;5</label>
###xml 969 1095 966 1091 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="55">Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of quinidine (1and 3&#160;&#956;M)</p>
###xml 969 1095 966 1091 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="55">Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of quinidine (1and 3&#160;&#956;M)</p></caption>
###xml 1095 1096 1091 1092 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 1096 1098 1092 1094 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">WT</th>
###xml 1098 1101 1094 1097 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">KPQ</th>
###xml 1095 1101 1091 1097 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="3">WT</th><th colspan="3">KPQ</th></tr>
###xml 1101 1108 1097 1104 <th xmlns:xlink="http://www.w3.org/1999/xlink">Control</th>
###xml 1108 1123 1104 1118 <th xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 1&#160;&#956;M</th>
###xml 1123 1138 1118 1132 <th xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 3&#160;&#956;M</th>
###xml 1138 1145 1132 1139 <th xmlns:xlink="http://www.w3.org/1999/xlink">Control</th>
###xml 1145 1160 1139 1153 <th xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 1&#160;&#956;M</th>
###xml 1160 1175 1153 1167 <th xmlns:xlink="http://www.w3.org/1999/xlink">Quinidine 3&#160;&#956;M</th>
###xml 1101 1175 1097 1167 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Control</th><th>Quinidine 1&#160;&#956;M</th><th>Quinidine 3&#160;&#956;M</th><th>Control</th><th>Quinidine 1&#160;&#956;M</th><th>Quinidine 3&#160;&#956;M</th></tr>
###xml 1095 1175 1091 1167 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="3">WT</th><th colspan="3">KPQ</th></tr><tr><th>Control</th><th>Quinidine 1&#160;&#956;M</th><th>Quinidine 3&#160;&#956;M</th><th>Control</th><th>Quinidine 1&#160;&#956;M</th><th>Quinidine 3&#160;&#956;M</th></tr></thead>
###xml 1175 1185 1167 1177 <td xmlns:xlink="http://www.w3.org/1999/xlink">PES (8&#160;Hz)</td>
###xml 1185 1188 1177 1180 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">6/6</td>
###xml 1188 1191 1180 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">6/6</td>
###xml 1191 1194 1183 1186 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">2/6</td>
###xml 1194 1198 1186 1190 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">2/10</td>
###xml 1198 1201 1190 1193 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">1/5</td>
###xml 1201 1204 1193 1196 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/5</td>
###xml 1175 1204 1167 1196 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>PES (8&#160;Hz)</td><td char="/" align="char">6/6</td><td char="/" align="char">6/6</td><td char="/" align="char">2/6</td><td char="/" align="char">2/10</td><td char="/" align="char">1/5</td><td char="/" align="char">0/5</td></tr>
###xml 1204 1215 1196 1207 <td xmlns:xlink="http://www.w3.org/1999/xlink">PES (10&#160;Hz)</td>
###xml 1215 1218 1207 1210 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">6/6</td>
###xml 1218 1221 1210 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">4/6</td>
###xml 1221 1224 1213 1216 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/6</td>
###xml 1224 1228 1216 1220 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">3/10</td>
###xml 1228 1231 1220 1223 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/5</td>
###xml 1231 1234 1223 1226 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/5</td>
###xml 1204 1234 1196 1226 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>PES (10&#160;Hz)</td><td char="/" align="char">6/6</td><td char="/" align="char">4/6</td><td char="/" align="char">0/6</td><td char="/" align="char">3/10</td><td char="/" align="char">0/5</td><td char="/" align="char">0/5</td></tr>
###xml 1234 1236 1226 1228 <td xmlns:xlink="http://www.w3.org/1999/xlink">BP</td>
###xml 1236 1239 1228 1231 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">4/6</td>
###xml 1239 1242 1231 1234 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">3/6</td>
###xml 1242 1245 1234 1237 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/6</td>
###xml 1245 1249 1237 1241 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/10</td>
###xml 1249 1252 1241 1244 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/5</td>
###xml 1252 1255 1244 1247 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="/" align="char">0/5</td>
###xml 1234 1255 1226 1247 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BP</td><td char="/" align="char">4/6</td><td char="/" align="char">3/6</td><td char="/" align="char">0/6</td><td char="/" align="char">0/10</td><td char="/" align="char">0/5</td><td char="/" align="char">0/5</td></tr>
###xml 1175 1255 1167 1247 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>PES (8&#160;Hz)</td><td char="/" align="char">6/6</td><td char="/" align="char">6/6</td><td char="/" align="char">2/6</td><td char="/" align="char">2/10</td><td char="/" align="char">1/5</td><td char="/" align="char">0/5</td></tr><tr><td>PES (10&#160;Hz)</td><td char="/" align="char">6/6</td><td char="/" align="char">4/6</td><td char="/" align="char">0/6</td><td char="/" align="char">3/10</td><td char="/" align="char">0/5</td><td char="/" align="char">0/5</td></tr><tr><td>BP</td><td char="/" align="char">4/6</td><td char="/" align="char">3/6</td><td char="/" align="char">0/6</td><td char="/" align="char">0/10</td><td char="/" align="char">0/5</td><td char="/" align="char">0/5</td></tr></tbody>
###xml 1095 1255 1091 1247 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">WT</th><th colspan="3">KPQ</th></tr><tr><th>Control</th><th>Quinidine 1&#160;&#956;M</th><th>Quinidine 3&#160;&#956;M</th><th>Control</th><th>Quinidine 1&#160;&#956;M</th><th>Quinidine 3&#160;&#956;M</th></tr></thead><tbody><tr><td>PES (8&#160;Hz)</td><td char="/" align="char">6/6</td><td char="/" align="char">6/6</td><td char="/" align="char">2/6</td><td char="/" align="char">2/10</td><td char="/" align="char">1/5</td><td char="/" align="char">0/5</td></tr><tr><td>PES (10&#160;Hz)</td><td char="/" align="char">6/6</td><td char="/" align="char">4/6</td><td char="/" align="char">0/6</td><td char="/" align="char">3/10</td><td char="/" align="char">0/5</td><td char="/" align="char">0/5</td></tr><tr><td>BP</td><td char="/" align="char">4/6</td><td char="/" align="char">3/6</td><td char="/" align="char">0/6</td><td char="/" align="char">0/10</td><td char="/" align="char">0/5</td><td char="/" align="char">0/5</td></tr></tbody></table>
###xml 1255 1375 1247 1367 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="56">Numbers of hearts in which at least one episode of AT occurred/total number of preparations studied under that condition</p>
###xml 1255 1375 1247 1367 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="56">Numbers of hearts in which at least one episode of AT occurred/total number of preparations studied under that condition</p></table-wrap-foot>
###xml 962 1375 959 1367 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab5"><label>Table&#160;5</label><caption><p textid="55">Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of quinidine (1and 3&#160;&#956;M)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">WT</th><th colspan="3">KPQ</th></tr><tr><th>Control</th><th>Quinidine 1&#160;&#956;M</th><th>Quinidine 3&#160;&#956;M</th><th>Control</th><th>Quinidine 1&#160;&#956;M</th><th>Quinidine 3&#160;&#956;M</th></tr></thead><tbody><tr><td>PES (8&#160;Hz)</td><td char="/" align="char">6/6</td><td char="/" align="char">6/6</td><td char="/" align="char">2/6</td><td char="/" align="char">2/10</td><td char="/" align="char">1/5</td><td char="/" align="char">0/5</td></tr><tr><td>PES (10&#160;Hz)</td><td char="/" align="char">6/6</td><td char="/" align="char">4/6</td><td char="/" align="char">0/6</td><td char="/" align="char">3/10</td><td char="/" align="char">0/5</td><td char="/" align="char">0/5</td></tr><tr><td>BP</td><td char="/" align="char">4/6</td><td char="/" align="char">3/6</td><td char="/" align="char">0/6</td><td char="/" align="char">0/10</td><td char="/" align="char">0/5</td><td char="/" align="char">0/5</td></tr></tbody></table><table-wrap-foot><p textid="56">Numbers of hearts in which at least one episode of AT occurred/total number of preparations studied under that condition</p></table-wrap-foot></table-wrap>
In common with flecainide, quinidine was anti-arrhythmic in both KPQ and WT hearts. Table 5 confirms that in the absence of added agent WT hearts were more arrhythmogenic than KPQ preparations, whether for PES conducted at 8 Hz (P = 0.007), 10 Hz (P = 0.01) and BP (P = 0.008). In WT hearts, quinidine reduced the number of WT hearts showing at least one arrhythmic episode whatever the procedure, with 3 muM more potent than 1 muM, to give a significant difference between test and control conditions with PES conducted at 10 Hz (P = 0.002). KPQ hearts showed low incidences of arrhythmogenesis both before and after quinidine treatment, which made distinguishing the incidences of hearts showing atrial arrhythmias difficult. Nevertheless, quinidine tended to diminish this incidence, with none of the KPQ hearts displaying arrhythmias after addition of 3 muM quinidine. BP proved to be less effective in inducing arrhythmogenesis in both experimental groups. Table 5Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of quinidine (1and 3 muM) WTKPQControlQuinidine 1 muMQuinidine 3 muMControlQuinidine 1 muMQuinidine 3 muMPES (8 Hz)6/66/62/62/101/50/5PES (10 Hz)6/64/60/63/100/50/5BP4/63/60/60/100/50/5Numbers of hearts in which at least one episode of AT occurred/total number of preparations studied under that condition
###end p 54
###begin p 55
Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of quinidine (1and 3 muM)
###end p 55
###begin p 56
Numbers of hearts in which at least one episode of AT occurred/total number of preparations studied under that condition
###end p 56
###begin p 57
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">overall</italic>
###xml 71 80 71 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per heart</italic>
###xml 318 319 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 474 475 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 493 494 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 513 514 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Table 4 shows the mean overall incidence of atrial arrhythmic episodes per heart in WT and KPQ groups in the presence and absence of 1 and 3 muM quinidine. In WT hearts, the presence of 1 muM quinidine significantly reduced the average total incidence of arrhythmic episodes per heart only for PES performed at 10 Hz (P = 0.01), while 3 muM quinidine reduced the average total incidence of arrhythmic episodes per heart for PES conducted at stimulation frequencies of 8 Hz (P = 0.008), 10 Hz (P < 0.0001) and BP (P = 0.02). The control mean total incidence of arrhythmic episodes per heart in KPQ hearts for a PES protocol was very small when compared to that in WT preparations, and no atrial arrhythmogenesis was detected with a BP procedure. Addition of quinidine did not result in any significant changes in the mean total incidence of arrhythmic episodes per heart for either BP or PES.
###end p 57
###begin p 58
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 51 65 51 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mean incidence</italic>
###xml 89 98 89 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per heart</italic>
###xml 296 297 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 317 318 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Table 4 also summarises the effect of quinidine on mean incidence of arrhythmic episodes per heart for each of the four different categories of arrhythmic durations. Quinidine (3 muM) significantly reduced the appearance only of arrhythmic episodes lasting </=1 s for PES conducted at both 8 Hz (P = 0.03) and 10 Hz (P = 0.0007) stimulation frequencies in WT hearts, but not for BP. Quinidine (1 muM) in WT hearts had no significant effect on the mean incidence of arrhythmic episodes per heart for any of the four different categories for either PES or BP. Quinidine (1 and 3 muM) in KPQ preparations did not have any significant effect on the mean incidence of arrhythmic episodes per heart for any of the four different categories for either PES or BP.
###end p 58
###begin title 59
Atrial monophasic action potential durations are longer in KPQ than in WT hearts
###end title 59
###begin p 60
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 134 136 134 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 414 416 414 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 633 635 632 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 650 651 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 681 682 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 720 721 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 855 857 849 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 897 899 891 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 920 921 912 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 965 966 955 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1164 1165 1154 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1308 1309 1295 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1347 1348 1332 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1385 1386 1368 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1422 1423 1403 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1464 1465 1445 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1499 1501 1480 1482 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1521 1522 1502 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1566 1567 1545 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1622 1623 1599 1600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1653 1659 1630 1636 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1778 1780 1755 1757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 1782 1783 1759 1760 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1789 1792 1766 1769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KPQ</italic>
###xml 1794 1795 1771 1772 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1812 1813 1789 1790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1815 1816 1792 1793 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1821 1822 1798 1799 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1853 1854 1829 1830 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1856 1857 1832 1833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1870 1871 1845 1846 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1873 1874 1848 1849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1908 1909 1882 1883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1911 1912 1885 1886 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1917 1918 1891 1892 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1936 1937 1910 1911 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1978 1987 1951 1960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open bars</italic>
###xml 1989 1992 1962 1965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KPQ</italic>
###xml 2016 2018 1988 1990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 2041 2051 2012 2022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 2064 2066 2035 2037 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 2146 2147 2117 2118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2175 2186 2146 2157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed bars</italic>
###xml 2213 2215 2184 2186 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 2306 2308 2277 2279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 2337 2338 2308 2309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1659 2348 1636 2319 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="61">Effect of flecainide and quinidine on atrial APDs in WT and KPQ hearts. MAPs recorded during regular pacing at 8&#160;Hz in <italic>WT</italic> (<bold>A</bold>) and <italic>KPQ</italic> (<bold>B</bold>) hearts before (<italic>a</italic>, <bold>A</bold> and <bold>B</bold>) and after addition of 1&#160;&#956;M (<bold>B</bold>, <italic>b</italic>) and 3&#160;&#956;M (<bold>A</bold>, <italic>b</italic>) flecainide and 3&#160;&#956;M quinidine (<italic>c</italic>, <bold>A</bold> and <bold>B</bold>). The bar chart (<bold>C</bold>) summarises effect of 1&#160;&#956;M flecainide (<italic>open bars</italic>; <italic>KPQ</italic>) and 3&#160;&#956;M flecainide (<italic>WT</italic>) and 3&#160;&#956;M quinidine (<italic>black bars</italic>) on mean APD<sub>90</sub> of both experimental groups. Stars represent significantly different results (*<italic>P</italic>&#8201;&lt;&#8201;0.0001) between control (<italic>dashed bars</italic>) and drug-treated mean APD<sub>90</sub> within each experimental group, while # indicates significantly different control mean APD<sub>90</sub> between WT and KPQ hearts (#<italic>P</italic>&#8201;&lt;&#8201;0.0001)</p>
###xml 1659 2348 1636 2319 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="61">Effect of flecainide and quinidine on atrial APDs in WT and KPQ hearts. MAPs recorded during regular pacing at 8&#160;Hz in <italic>WT</italic> (<bold>A</bold>) and <italic>KPQ</italic> (<bold>B</bold>) hearts before (<italic>a</italic>, <bold>A</bold> and <bold>B</bold>) and after addition of 1&#160;&#956;M (<bold>B</bold>, <italic>b</italic>) and 3&#160;&#956;M (<bold>A</bold>, <italic>b</italic>) flecainide and 3&#160;&#956;M quinidine (<italic>c</italic>, <bold>A</bold> and <bold>B</bold>). The bar chart (<bold>C</bold>) summarises effect of 1&#160;&#956;M flecainide (<italic>open bars</italic>; <italic>KPQ</italic>) and 3&#160;&#956;M flecainide (<italic>WT</italic>) and 3&#160;&#956;M quinidine (<italic>black bars</italic>) on mean APD<sub>90</sub> of both experimental groups. Stars represent significantly different results (*<italic>P</italic>&#8201;&lt;&#8201;0.0001) between control (<italic>dashed bars</italic>) and drug-treated mean APD<sub>90</sub> within each experimental group, while # indicates significantly different control mean APD<sub>90</sub> between WT and KPQ hearts (#<italic>P</italic>&#8201;&lt;&#8201;0.0001)</p></caption>
###xml 2348 2348 2319 2319 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2008_633_Fig4_HTML" id="MO4"/>
###xml 1653 2348 1630 2319 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="61">Effect of flecainide and quinidine on atrial APDs in WT and KPQ hearts. MAPs recorded during regular pacing at 8&#160;Hz in <italic>WT</italic> (<bold>A</bold>) and <italic>KPQ</italic> (<bold>B</bold>) hearts before (<italic>a</italic>, <bold>A</bold> and <bold>B</bold>) and after addition of 1&#160;&#956;M (<bold>B</bold>, <italic>b</italic>) and 3&#160;&#956;M (<bold>A</bold>, <italic>b</italic>) flecainide and 3&#160;&#956;M quinidine (<italic>c</italic>, <bold>A</bold> and <bold>B</bold>). The bar chart (<bold>C</bold>) summarises effect of 1&#160;&#956;M flecainide (<italic>open bars</italic>; <italic>KPQ</italic>) and 3&#160;&#956;M flecainide (<italic>WT</italic>) and 3&#160;&#956;M quinidine (<italic>black bars</italic>) on mean APD<sub>90</sub> of both experimental groups. Stars represent significantly different results (*<italic>P</italic>&#8201;&lt;&#8201;0.0001) between control (<italic>dashed bars</italic>) and drug-treated mean APD<sub>90</sub> within each experimental group, while # indicates significantly different control mean APD<sub>90</sub> between WT and KPQ hearts (#<italic>P</italic>&#8201;&lt;&#8201;0.0001)</p></caption><graphic position="anchor" xlink:href="424_2008_633_Fig4_HTML" id="MO4"/></fig>
Figure 4 illustrates the effects of flecainide and quinidine on atrial action potential durations at the 90% repolarisation level (APD90) in WT and KPQ hearts. In these experiments, hearts were regularly paced at 8 Hz; at the faster pacing frequency of 10 Hz, it was often not possible clearly to demonstrate full recovery of the action potential to baseline, which was necessary for a full characterisation of APD90 values. It displays action potential waveforms in WT (A) and KPQ hearts (B), before (a) and following addition of flecainide (b) and quinidine (c). Flecainide 3 muM (Ab and open bars in C) significantly prolonged APD90 in WT hearts (P < 0.0001) from 22.1 +/- 0.4 (n = 13, seven hearts) to 27.3 +/- 0.8 (n = 13, six hearts) but failed to ensure consistent capture in KPQ hearts. A lower concentration of 1 muM flecainide did not change APD90 in KPQ hearts, with values for mean APD90 being 24.5 +/- 0.3 (n = 17, ten hearts) before and 23.9 +/- 0.7 (n = 11, seven hearts) after addition of the drug (Bb and open bars in C). Monophasic action potential waveforms (MAPs) recorded during regular pacing at 8 Hz in WT and KPQ hearts both significantly (P < 0.0001 for both groups) increased in duration on addition of 3 muM quinidine (c, A and B, respectively, black bars in C) from 22.1 +/- 0.4 (n = 13, seven hearts) to 31.0 +/- 0.6 (n = 8, four hearts) and 24.5 +/- 0.3 (n = 17, ten hearts) to 32.3 +/- 0.6 (n = 7, four hearts), respectively. Figure 4C also shows that control mean APD90 was significantly (P < 0.0001 (#)) longer in KPQ (24.5 +/- 0.3 (n = 17, ten hearts)) when compared to WT (22.1 +/- 0.4 (n = 13, seven hearts)) hearts. Fig. 4Effect of flecainide and quinidine on atrial APDs in WT and KPQ hearts. MAPs recorded during regular pacing at 8 Hz in WT (A) and KPQ (B) hearts before (a, A and B) and after addition of 1 muM (B, b) and 3 muM (A, b) flecainide and 3 muM quinidine (c, A and B). The bar chart (C) summarises effect of 1 muM flecainide (open bars; KPQ) and 3 muM flecainide (WT) and 3 muM quinidine (black bars) on mean APD90 of both experimental groups. Stars represent significantly different results (*P < 0.0001) between control (dashed bars) and drug-treated mean APD90 within each experimental group, while # indicates significantly different control mean APD90 between WT and KPQ hearts (#P < 0.0001)
###end p 60
###begin p 61
###xml 119 121 119 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 123 124 123 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 130 133 130 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KPQ</italic>
###xml 135 136 135 136 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 153 154 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 156 157 156 157 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 162 163 162 163 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 194 195 193 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 197 198 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 211 212 209 210 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 214 215 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 249 250 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 252 253 249 250 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 258 259 255 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 277 278 274 275 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 319 328 315 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open bars</italic>
###xml 330 333 326 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KPQ</italic>
###xml 357 359 352 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 382 392 376 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 405 407 399 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 487 488 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 516 527 510 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed bars</italic>
###xml 554 556 548 550 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 647 649 641 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 678 679 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Effect of flecainide and quinidine on atrial APDs in WT and KPQ hearts. MAPs recorded during regular pacing at 8 Hz in WT (A) and KPQ (B) hearts before (a, A and B) and after addition of 1 muM (B, b) and 3 muM (A, b) flecainide and 3 muM quinidine (c, A and B). The bar chart (C) summarises effect of 1 muM flecainide (open bars; KPQ) and 3 muM flecainide (WT) and 3 muM quinidine (black bars) on mean APD90 of both experimental groups. Stars represent significantly different results (*P < 0.0001) between control (dashed bars) and drug-treated mean APD90 within each experimental group, while # indicates significantly different control mean APD90 between WT and KPQ hearts (#P < 0.0001)
###end p 61
###begin title 62
KPQ hearts have longer atrial refractory periods than WT hearts
###end title 62
###begin p 63
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 136 143 136 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">reduced</italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">both</italic>
###xml 322 331 322 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">increased</italic>
###xml 342 344 342 344 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 498 500 498 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 542 551 542 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">increased</italic>
###xml 555 557 555 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 726 727 726 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 889 890 889 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 967 968 965 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1037 1038 1033 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1102 1103 1096 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1139 1140 1131 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1207 1213 1199 1205 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 1335 1336 1327 1328 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1349 1350 1341 1342 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1364 1375 1356 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed bars</italic>
###xml 1417 1426 1408 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open bars</italic>
###xml 1450 1460 1440 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 1550 1551 1540 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1686 1687 1674 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 1844 1845 1831 1832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1213 1859 1205 1846 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="64">Effect of flecainide on mean atrial effective refractory periods (AERP) in WT and KPQ hearts. AERPs observed during 8&#160;Hz (<bold>A</bold>) and 10&#160;Hz (<bold>B</bold>) PES before (<italic>dashed bars</italic>) and after addition of 1&#160;&#956;M flecainide (<italic>open bars</italic>) and 3&#160;&#956;M flecainide (<italic>black bars</italic>) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***<italic>P</italic>&#8201;&lt;&#8201;0.0001) and compare AERP between control and 1&#160;&#956;M flecainide and control and 3&#160;&#956;M flecainide for KPQ and WT groups, respectively. <italic>X</italic> marking represents loss of capture with 3&#160;&#956;M flecainide for KPQ preparations. The results comparing control AERP between WT and KPQ groups are also shown (<italic>P</italic>&#8201;&lt;&#8201;0.0001 (#))</p>
###xml 1213 1859 1205 1846 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="64">Effect of flecainide on mean atrial effective refractory periods (AERP) in WT and KPQ hearts. AERPs observed during 8&#160;Hz (<bold>A</bold>) and 10&#160;Hz (<bold>B</bold>) PES before (<italic>dashed bars</italic>) and after addition of 1&#160;&#956;M flecainide (<italic>open bars</italic>) and 3&#160;&#956;M flecainide (<italic>black bars</italic>) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***<italic>P</italic>&#8201;&lt;&#8201;0.0001) and compare AERP between control and 1&#160;&#956;M flecainide and control and 3&#160;&#956;M flecainide for KPQ and WT groups, respectively. <italic>X</italic> marking represents loss of capture with 3&#160;&#956;M flecainide for KPQ preparations. The results comparing control AERP between WT and KPQ groups are also shown (<italic>P</italic>&#8201;&lt;&#8201;0.0001 (#))</p></caption>
###xml 1859 1859 1846 1846 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2008_633_Fig5_HTML" id="MO5"/>
###xml 1207 1859 1199 1846 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="64">Effect of flecainide on mean atrial effective refractory periods (AERP) in WT and KPQ hearts. AERPs observed during 8&#160;Hz (<bold>A</bold>) and 10&#160;Hz (<bold>B</bold>) PES before (<italic>dashed bars</italic>) and after addition of 1&#160;&#956;M flecainide (<italic>open bars</italic>) and 3&#160;&#956;M flecainide (<italic>black bars</italic>) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***<italic>P</italic>&#8201;&lt;&#8201;0.0001) and compare AERP between control and 1&#160;&#956;M flecainide and control and 3&#160;&#956;M flecainide for KPQ and WT groups, respectively. <italic>X</italic> marking represents loss of capture with 3&#160;&#956;M flecainide for KPQ preparations. The results comparing control AERP between WT and KPQ groups are also shown (<italic>P</italic>&#8201;&lt;&#8201;0.0001 (#))</p></caption><graphic position="anchor" xlink:href="424_2008_633_Fig5_HTML" id="MO5"/></fig>
In contrast to previous studies of ventricular arrhythmogenesis [39, 40], the present experiments demonstrated that KPQ hearts showed a reduced propensity to atrial arrhythmogenesis compared to WT, and this tendency was reduced further by both flecainide and quinidine in both genetic variants. Yet KPQ hearts also showed increased atrial APD90 values compared to WT hearts. Furthermore, flecainide and quinidine exerted anti-arrhythmic effects in both KPQ and WT. Yet flecainide also increased APD90 in WT, and both flecainide and quinidine increased APD90 in KPQ hearts. However comparisons of refractory periods in KPQ and WT hearts provided possible correlates with their contrasting arrhythmogenic properties. Thus, Fig. 5 shows significantly longer mean AERPs in KPQ hearts compared to WT hearts when these were subject to PES conducted at either 8 or 10 Hz stimulation frequencies (P < 0.0001 for both). AERP observed at 8 Hz in WT hearts was 14.0 +/- 1.0 ms (n = 30, eight hearts) and in KPQ hearts was equal to 21.3 +/- 0.7 ms (n = 41, 16 hearts). At 10 Hz, these values were 13.7 +/- 0.8 ms (n = 33, 15 hearts) and 21.2 +/- 0.8 (n = 43, 15 hearts) in WT and KPQ experimental groups, respectively. Fig. 5Effect of flecainide on mean atrial effective refractory periods (AERP) in WT and KPQ hearts. AERPs observed during 8 Hz (A) and 10 Hz (B) PES before (dashed bars) and after addition of 1 muM flecainide (open bars) and 3 muM flecainide (black bars) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***P < 0.0001) and compare AERP between control and 1 muM flecainide and control and 3 muM flecainide for KPQ and WT groups, respectively. X marking represents loss of capture with 3 muM flecainide for KPQ preparations. The results comparing control AERP between WT and KPQ groups are also shown (P < 0.0001 (#))
###end p 63
###begin p 64
###xml 122 123 122 123 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 136 137 136 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 151 162 151 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed bars</italic>
###xml 204 213 203 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open bars</italic>
###xml 237 247 235 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 337 338 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 473 474 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 631 632 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Effect of flecainide on mean atrial effective refractory periods (AERP) in WT and KPQ hearts. AERPs observed during 8 Hz (A) and 10 Hz (B) PES before (dashed bars) and after addition of 1 muM flecainide (open bars) and 3 muM flecainide (black bars) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***P < 0.0001) and compare AERP between control and 1 muM flecainide and control and 3 muM flecainide for KPQ and WT groups, respectively. X marking represents loss of capture with 3 muM flecainide for KPQ preparations. The results comparing control AERP between WT and KPQ groups are also shown (P < 0.0001 (#))
###end p 64
###begin title 65
Flecainide and quinidine both prolong the refractory periods in both WT and KPQ hearts
###end title 65
###begin p 66
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 223 224 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 262 263 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 309 310 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 345 346 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 454 455 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 561 562 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 600 601 585 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 678 679 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 860 861 844 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 882 883 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1050 1051 1031 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1086 1087 1065 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1138 1139 1115 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1174 1175 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1229 1230 1204 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Figure 5 also shows effect of 1 and 3 muM flecainide on AERP in WT and KPQ hearts obtained during PES conducted at 8 Hz (A) and 10 Hz (B) stimulation frequencies. A highly significant increase in AERP from 14.0 +/- 1.0 ms (n = 30, eight hearts) to 29.9 +/- 2.5 (n = 14, five hearts) and from 13.7 +/- 0.8 ms (n = 33, 15 hearts) to 45.3 +/- 4.7 (n = 17, six hearts) was observed in WT hearts at 8 and 10 Hz, respectively, on addition of 1 muM flecainide (P < 0.0001 for both frequencies). Flecainide (3 muM) further significantly increased AERP to 58.4 +/- 4.3 (n = 9, three hearts) and 75.0 +/- 5.9 (n = 8, three hearts) at stimulation frequencies of 8 and 10 Hz, respectively (P < 0.0001). In addition, the differences in AERP between results from using 1 and 3 muM concentrations of the drug were also significant whether at stimulation frequencies of 8 Hz (P < 0.0001) or 10 Hz (P = 0.001). However, KPQ hearts showed a failure of consistent stimulus capture with 3 muM flecainide. AERP significantly increased in this group from 21.3 +/- 0.7 ms (n = 41, 16 hearts) to 45.0 +/- 2.7 (n = 17, six hearts) at 8 Hz, and from 21.2 +/- 0.8 (n = 43, 15 hearts) to 55.5 +/- 4.8 (n = 11, five hearts) at a 10 Hz stimulation frequency (P < 0.0001 for both frequencies) with 1 muM flecainide.
###end p 66
###begin p 67
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 231 232 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 267 268 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 347 348 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 399 400 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 469 470 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 574 575 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 613 614 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 694 695 681 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 823 824 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 844 845 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 955 956 939 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 991 992 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1038 1039 1018 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1074 1075 1052 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1170 1171 1147 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1273 1274 1247 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1312 1313 1284 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1388 1389 1360 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1501 1502 1472 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1512 1518 1483 1489 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 1601 1602 1572 1573 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1615 1616 1586 1587 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1630 1641 1601 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed bars</italic>
###xml 1682 1691 1652 1661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open bars</italic>
###xml 1714 1724 1683 1693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 1814 1815 1783 1784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1828 1829 1797 1798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2039 2040 2006 2007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1518 2050 1489 2017 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="68">Effect of quinidine on mean AERP in WT and KPQ hearts. AERPs observed during 8&#160;Hz (<bold>A</bold>) and 10&#160;Hz (<bold>B</bold>) PES before (<italic>dashed bars</italic>) and after addition of 1&#160;&#956;M quinidine (<italic>open bars</italic>) and 3&#160;&#956;M quinidine (<italic>black bars</italic>) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***<italic>P</italic>&#8201;&lt;&#8201;0.0001, **<italic>P</italic>&#8201;&lt;&#8201;0.001) and compare AERP between control and 1&#160;&#956;M quinidine and control and 3&#160;&#956;M quinidine for KPQ and WT groups, respectively. The results comparing control AERP between WT and KPQ groups are also shown (#<italic>P</italic>&#8201;&lt;&#8201;0.0001)</p>
###xml 1518 2050 1489 2017 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="68">Effect of quinidine on mean AERP in WT and KPQ hearts. AERPs observed during 8&#160;Hz (<bold>A</bold>) and 10&#160;Hz (<bold>B</bold>) PES before (<italic>dashed bars</italic>) and after addition of 1&#160;&#956;M quinidine (<italic>open bars</italic>) and 3&#160;&#956;M quinidine (<italic>black bars</italic>) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***<italic>P</italic>&#8201;&lt;&#8201;0.0001, **<italic>P</italic>&#8201;&lt;&#8201;0.001) and compare AERP between control and 1&#160;&#956;M quinidine and control and 3&#160;&#956;M quinidine for KPQ and WT groups, respectively. The results comparing control AERP between WT and KPQ groups are also shown (#<italic>P</italic>&#8201;&lt;&#8201;0.0001)</p></caption>
###xml 2050 2050 2017 2017 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2008_633_Fig6_HTML" id="MO6"/>
###xml 1512 2050 1483 2017 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="68">Effect of quinidine on mean AERP in WT and KPQ hearts. AERPs observed during 8&#160;Hz (<bold>A</bold>) and 10&#160;Hz (<bold>B</bold>) PES before (<italic>dashed bars</italic>) and after addition of 1&#160;&#956;M quinidine (<italic>open bars</italic>) and 3&#160;&#956;M quinidine (<italic>black bars</italic>) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***<italic>P</italic>&#8201;&lt;&#8201;0.0001, **<italic>P</italic>&#8201;&lt;&#8201;0.001) and compare AERP between control and 1&#160;&#956;M quinidine and control and 3&#160;&#956;M quinidine for KPQ and WT groups, respectively. The results comparing control AERP between WT and KPQ groups are also shown (#<italic>P</italic>&#8201;&lt;&#8201;0.0001)</p></caption><graphic position="anchor" xlink:href="424_2008_633_Fig6_HTML" id="MO6"/></fig>
Figure 6 illustrates effects of 1 and 3 muM quinidine on AERP in WT and KPQ hearts obtained during PES conducted at 8 Hz (A) and 10 Hz (B) stimulation frequencies. In WT hearts, a significant increase in AERP from 13.7 +/- 0.8 ms (n = 33, 15 hearts) to 19.4 +/- 1.2 (n = 13, five hearts) on addition of 1 muM quinidine was only observed at 10 Hz (P < 0.001). AERP further increased to 53.7 +/- 2.7 (n = 17, six hearts) in addition of 3 muM quinidine at this frequency (P < 0.0001). The same concentration of quinidine also significantly increased AERP from 14.0 +/- 1.0 ms (n = 30, eight hearts) to 35.6 +/- 3.5 (n = 19, six hearts) at an 8 Hz stimulation frequency in this experimental group (P < 0.0001). In addition, AERPs obtained at 1 and 3 muM concentrations of the drug were significantly different whether at 8 Hz (P = 0.03) and 10 Hz (P < 0.0001) stimulation frequencies. In KPQ hearts a highly significant increase in AERP from 21.3 +/- 0.7 ms (n = 41, 16 hearts) to 37.2 +/- 4.0 (n = 14, four hearts) and from 21.2 +/- 0.8 ms (n = 43, 15 hearts) to 51.3 +/- 8.6 (n = 12, four hearts) was observed at 8 and 10 Hz, respectively, in addition of quinidine 1 muM (P < 0.0001 for both frequencies). Quinidine (3 muM) also significantly increased AERP to 35.4 +/- 1.8 (n = 15, five hearts) and 47.7 +/- 3.7 (n = 15, five hearts) at 8 and 10 Hz, respectively when compared to control (P < 0.0001) in mutant hearts, doing so to similar extents as obtained with 1 muM quinidine for either frequency (P > 0.05). Fig. 6Effect of quinidine on mean AERP in WT and KPQ hearts. AERPs observed during 8 Hz (A) and 10 Hz (B) PES before (dashed bars) and after addition of 1 muM quinidine (open bars) and 3 muM quinidine (black bars) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***P < 0.0001, **P < 0.001) and compare AERP between control and 1 muM quinidine and control and 3 muM quinidine for KPQ and WT groups, respectively. The results comparing control AERP between WT and KPQ groups are also shown (#P < 0.0001)
###end p 67
###begin p 68
###xml 83 84 83 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 97 98 97 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 112 123 112 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed bars</italic>
###xml 164 173 163 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open bars</italic>
###xml 196 206 194 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 296 297 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 310 311 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 521 522 517 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Effect of quinidine on mean AERP in WT and KPQ hearts. AERPs observed during 8 Hz (A) and 10 Hz (B) PES before (dashed bars) and after addition of 1 muM quinidine (open bars) and 3 muM quinidine (black bars) to WT and KPQ hearts. The results of one-way ANOVA for correlated samples are shown (***P < 0.0001, **P < 0.001) and compare AERP between control and 1 muM quinidine and control and 3 muM quinidine for KPQ and WT groups, respectively. The results comparing control AERP between WT and KPQ groups are also shown (#P < 0.0001)
###end p 68
###begin title 69
Arrhythmogenic tendency correlates with increased local critical intervals
###end title 69
###begin p 70
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 117 119 117 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 279 281 279 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 515 517 515 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 17 23 <span type="species:ncbi:10090">murine</span>
Previous work on murine ventricular arrhythmogenecity [27] demonstrated increased risks of re-excitation when the APD90 exceeded the ventricular effective refractory period (VERP). We tested such a hypothesis for the atria studied here by comparing the above values of atrial APD90 and AERP in both WT and KPQ groups in the presence and the absence of flecainide and quinidine. We hypothesised that the risk of local re-excitation might be reflected in a critical interval (CI) given by the relevant difference (APD90-AERP).
###end p 70
###begin p 71
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 152 154 152 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 338 340 338 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 577 578 569 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 592 593 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 677 685 669 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">positive</italic>
###xml 755 756 747 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 900 902 892 894 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1028 1036 1020 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">negative</italic>
###xml 1107 1108 1099 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1201 1203 1193 1195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1371 1373 1363 1365 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1484 1486 1476 1478 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1513 1514 1505 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1655 1656 1647 1648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1844 1845 1836 1837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1927 1929 1919 1921 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 2067 2069 2059 2061 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 2071 2077 2063 2069 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;7</label>
###xml 2227 2230 2219 2222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APD</italic>
###xml 2230 2232 2222 2224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">90</italic>
###xml 2230 2232 2222 2224 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>90</italic></sub>
###xml 2271 2275 2263 2267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AERP</italic>
###xml 2307 2309 2299 2301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CI</italic>
###xml 2318 2319 2310 2311 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 2330 2331 2322 2323 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 2348 2349 2340 2341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 2351 2352 2343 2344 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 2357 2358 2349 2350 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 2394 2395 2386 2387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2397 2398 2389 2390 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 2403 2404 2395 2396 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 2421 2422 2413 2414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 2424 2425 2416 2417 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 2430 2431 2422 2423 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 2511 2512 2503 2504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 2514 2515 2506 2507 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 2520 2521 2512 2513 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 2557 2558 2549 2550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2560 2561 2552 2553 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 2566 2567 2558 2559 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 2584 2585 2576 2577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 2587 2588 2579 2580 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 2593 2594 2585 2586 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 2609 2611 2601 2603 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 2613 2634 2605 2626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vertical dashed lines</italic>
###xml 2643 2663 2635 2655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vertical solid lines</italic>
###xml 2680 2687 2672 2679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">shading</italic>
###xml 2690 2699 2682 2691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Asterisks</italic>
###xml 2745 2746 2737 2738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2759 2760 2751 2752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2855 2856 2847 2848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2077 2913 2069 2905 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="72">Effect of flecainide and quinidine on mean critical interval in WT and KPQ hearts. Changes in atrial action potential duration at 90% repolarization (<italic>APD</italic><sub><italic>90</italic></sub>), atrial effective refractory period (<italic>AERP</italic>), and local critical interval (<italic>CI</italic>) in WT (<bold>A</bold>) and KPQ (<bold>B</bold>) hearts before (<italic>a</italic>, <bold>A</bold> and <bold>B</bold>) and after exposure to flecainide (<italic>b</italic>, <bold>A</bold> and <bold>B</bold>) and quinidine (<italic>c</italic>, <bold>A</bold> and <bold>B</bold>). MAP waveforms during regular stimulation at 8&#160;Hz frequency in hearts before (<italic>a</italic>, <bold>A</bold> and <bold>B</bold>) and after exposure to flecainide (<italic>b</italic>, <bold>A</bold> and <bold>B</bold>) and quinidine (<italic>c</italic>, <bold>A</bold> and <bold>B</bold>) comparing APD<sub>90</sub> (<italic>vertical dashed lines</italic>), AERP (<italic>vertical solid lines</italic>), and local CI (<italic>shading</italic>). <italic>Asterisks</italic> indicate CI values that are significantly (**<italic>P</italic>&#8201;&lt;&#8201;0.001; ***<italic>P</italic>&#8201;&lt;&#8201;0.0001) different before and after addition of a drug, and # those that are significantly (#<italic>P</italic>&#8201;&lt;&#8201;0.001) different between WT and KPQ hearts at baseline</p>
###xml 2077 2913 2069 2905 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="72">Effect of flecainide and quinidine on mean critical interval in WT and KPQ hearts. Changes in atrial action potential duration at 90% repolarization (<italic>APD</italic><sub><italic>90</italic></sub>), atrial effective refractory period (<italic>AERP</italic>), and local critical interval (<italic>CI</italic>) in WT (<bold>A</bold>) and KPQ (<bold>B</bold>) hearts before (<italic>a</italic>, <bold>A</bold> and <bold>B</bold>) and after exposure to flecainide (<italic>b</italic>, <bold>A</bold> and <bold>B</bold>) and quinidine (<italic>c</italic>, <bold>A</bold> and <bold>B</bold>). MAP waveforms during regular stimulation at 8&#160;Hz frequency in hearts before (<italic>a</italic>, <bold>A</bold> and <bold>B</bold>) and after exposure to flecainide (<italic>b</italic>, <bold>A</bold> and <bold>B</bold>) and quinidine (<italic>c</italic>, <bold>A</bold> and <bold>B</bold>) comparing APD<sub>90</sub> (<italic>vertical dashed lines</italic>), AERP (<italic>vertical solid lines</italic>), and local CI (<italic>shading</italic>). <italic>Asterisks</italic> indicate CI values that are significantly (**<italic>P</italic>&#8201;&lt;&#8201;0.001; ***<italic>P</italic>&#8201;&lt;&#8201;0.0001) different before and after addition of a drug, and # those that are significantly (#<italic>P</italic>&#8201;&lt;&#8201;0.001) different between WT and KPQ hearts at baseline</p></caption>
###xml 2913 2913 2905 2905 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2008_633_Fig7_HTML" id="MO7"/>
###xml 2071 2913 2063 2905 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>Fig.&#160;7</label><caption><p textid="72">Effect of flecainide and quinidine on mean critical interval in WT and KPQ hearts. Changes in atrial action potential duration at 90% repolarization (<italic>APD</italic><sub><italic>90</italic></sub>), atrial effective refractory period (<italic>AERP</italic>), and local critical interval (<italic>CI</italic>) in WT (<bold>A</bold>) and KPQ (<bold>B</bold>) hearts before (<italic>a</italic>, <bold>A</bold> and <bold>B</bold>) and after exposure to flecainide (<italic>b</italic>, <bold>A</bold> and <bold>B</bold>) and quinidine (<italic>c</italic>, <bold>A</bold> and <bold>B</bold>). MAP waveforms during regular stimulation at 8&#160;Hz frequency in hearts before (<italic>a</italic>, <bold>A</bold> and <bold>B</bold>) and after exposure to flecainide (<italic>b</italic>, <bold>A</bold> and <bold>B</bold>) and quinidine (<italic>c</italic>, <bold>A</bold> and <bold>B</bold>) comparing APD<sub>90</sub> (<italic>vertical dashed lines</italic>), AERP (<italic>vertical solid lines</italic>), and local CI (<italic>shading</italic>). <italic>Asterisks</italic> indicate CI values that are significantly (**<italic>P</italic>&#8201;&lt;&#8201;0.001; ***<italic>P</italic>&#8201;&lt;&#8201;0.0001) different before and after addition of a drug, and # those that are significantly (#<italic>P</italic>&#8201;&lt;&#8201;0.001) different between WT and KPQ hearts at baseline</p></caption><graphic position="anchor" xlink:href="424_2008_633_Fig7_HTML" id="MO7"/></fig>
Figure 7 illustrates typical action potential waveforms during regular pacing at 8 Hz recorded from WT (A) and KPQ (B) hearts with the corresponding APD90s (horizontal broken lines and clear shading), AERPs (horizontal solid lines and black shading), and local CIs (shading and hashing) shown below each one. Under control conditions, APD90 in WT (22.1 +/- 0.4 ms) and KPQ (24.5 +/- 0.3 ms) were significantly larger than the corresponding AERP (14 +/- 1.0 and 21.3 +/- 0.7 ms) (A and B, a). However, this difference was more significant in the WT group than in the KPQ group (P < 0.0001 and P = 0.005, respectively). This is reflected in WT hearts having significantly larger positive CI values when compared to KPQ hearts (8.1 and 3.2 ms, respectively; P < 0.001) which is clearly demonstrated in a larger shaded area on the WT group AP waveform (A and B, a). Flecainide significantly prolonged APD90 in WT but not in KPQ hearts and significantly increased AERP in both experimental groups (see findings above). The resulting negative CIs were -31.1 and -21.1 ms in WT and KPQ preparations, respectively (P < 0.0001 for both), indicating that the drug prolonged AERP to a much larger extent than APD90 in both groups. Accordingly, the solid vertical line (AERP) moved further to the right on action potential waveform while the position of the dashed vertical line (APD90) moved slightly to the right (WT) or remained virtually unchanged (KPQ). Quinidine significantly prolonged APD90 in both genetic variants (P < 0.0001 for both) moving the dashed line to the right. However, the drug also significantly prolonged AERP in the two experimental groups (P < 0.0001 for both), also moving the solid vertical line to the right. The resulting negative CIs were -4.6 (WT) and -3.1 ms (KPQ), and were significantly different from the control data (P < 0.001 for both groups). In contrast to flecainide, quinidine prolonged both APD90 and AERP similarly in the two groups, which resulted in smaller CI values that were still negative because the AERPs were longer than APD90. Fig. 7Effect of flecainide and quinidine on mean critical interval in WT and KPQ hearts. Changes in atrial action potential duration at 90% repolarization (APD90), atrial effective refractory period (AERP), and local critical interval (CI) in WT (A) and KPQ (B) hearts before (a, A and B) and after exposure to flecainide (b, A and B) and quinidine (c, A and B). MAP waveforms during regular stimulation at 8 Hz frequency in hearts before (a, A and B) and after exposure to flecainide (b, A and B) and quinidine (c, A and B) comparing APD90 (vertical dashed lines), AERP (vertical solid lines), and local CI (shading). Asterisks indicate CI values that are significantly (**P < 0.001; ***P < 0.0001) different before and after addition of a drug, and # those that are significantly (#P < 0.001) different between WT and KPQ hearts at baseline
###end p 71
###begin p 72
###xml 150 153 150 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APD</italic>
###xml 153 155 153 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">90</italic>
###xml 153 155 153 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>90</italic></sub>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AERP</italic>
###xml 230 232 230 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CI</italic>
###xml 241 242 241 242 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 253 254 253 254 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 274 275 274 275 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 280 281 280 281 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 317 318 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 320 321 320 321 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 326 327 326 327 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 344 345 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 347 348 347 348 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 353 354 353 354 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 437 438 437 438 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 443 444 443 444 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 480 481 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 483 484 483 484 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 489 490 489 490 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 510 511 510 511 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 516 517 516 517 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 532 534 532 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 536 557 536 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vertical dashed lines</italic>
###xml 566 586 566 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vertical solid lines</italic>
###xml 603 610 603 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">shading</italic>
###xml 613 622 613 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Asterisks</italic>
###xml 668 669 668 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 682 683 682 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 778 779 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Effect of flecainide and quinidine on mean critical interval in WT and KPQ hearts. Changes in atrial action potential duration at 90% repolarization (APD90), atrial effective refractory period (AERP), and local critical interval (CI) in WT (A) and KPQ (B) hearts before (a, A and B) and after exposure to flecainide (b, A and B) and quinidine (c, A and B). MAP waveforms during regular stimulation at 8 Hz frequency in hearts before (a, A and B) and after exposure to flecainide (b, A and B) and quinidine (c, A and B) comparing APD90 (vertical dashed lines), AERP (vertical solid lines), and local CI (shading). Asterisks indicate CI values that are significantly (**P < 0.001; ***P < 0.0001) different before and after addition of a drug, and # those that are significantly (#P < 0.001) different between WT and KPQ hearts at baseline
###end p 72
###begin title 73
Discussion
###end title 73
###begin p 74
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCN5A</italic>
###xml 151 152 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 185 186 181 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 209 211 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 398 400 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 402 404 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 629 631 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 643 649 639 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">atrial</italic>
###xml 693 695 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 407 415 <span type="species:ncbi:9606">Patients</span>
###xml 683 691 <span type="species:ncbi:9606">patients</span>
Human LQT3 syndrome results from 'gain-of-function' mutations in the SCN5A gene encoding the pore-forming alpha-subunit of the cardiac voltage-gated Na+ channel, producing incomplete Na+ channel inactivation [47]. This prolongs the cardiac APD in turn predisposing the myocardium to early EADs that can trigger life-threatening polymorphic ventricular tachyarrhythmias known as torsade de pointes [41, 44]. Patients with different LQTS variants demonstrated abnormalities in atrial physiology similar to those found in the ventricle in the form of prolonged APD and RP durations, and EADs triggering 'atrial torsade de pointes' [14]. However, atrial arrhythmias are uncommon in LQT3 patients [43].
###end p 74
###begin p 75
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 369 371 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 373 375 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 377 379 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 800 802 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 968 970 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 972 974 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 145 151 <span type="species:ncbi:10090">murine</span>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
The present experiments accordingly compared atrial arrhythmogenicity and its physiological basis in isolated perfused WT and Scn5a+/Delta (KPQ) murine hearts modelling human LQT3 for the first time. Experimental conditions thus differed from those used in some recent reports on atrial arrhythmogenesis of electrocardiographic studies in intact anaesthetised animals [29, 32, 37] as opposed to isolated perfused hearts. This may account for some of the differences in arrhythmogenecity seen in the control situations between the present and those previous studies. KPQ mice have previously been shown to provide useful cardiac models for the investigation of ventricular arrhythmogenesis in LQT3. Their hearts showed a marked susceptibility to such arrhythmias, in agreement with clinical findings [12]. Furthermore, pharmacological intervention using the cardiotropic agents flecainide and quinidine, respectively, alleviated and exacerbated such arrhythmogenicity [39, 40] likely through actions on inhomogeneities of APD through the thickness of the ventricular wall.
###end p 75
###begin p 76
###xml 35 41 <span type="species:ncbi:10090">murine</span>
However, unlike the ventricle, the murine atrium is a thin-walled structure unlikely to generate such spatial heterogeneities between epicardial and endocardial layers. This difference would be consistent with distinct mechanisms for atrial and ventricular arrhythmogenesis. We initially assessed atrial arrhythmic tendency in WT and genetically modified KPQ Langendorff-perfused heart preparations in the presence and absence of the same pharmacological interventions as cited above using both PES and BP protocols. These techniques both showed that a significantly greater proportion of WT hearts were arrhythmogenic compared to KPQ hearts. In addition, where it occurred, the average duration of atrial arrhythmia was longer in WT when compared to KPQ hearts. Therefore, it appears that the KPQ mutation exerts a surprising 'protective' effect against atrial arrhythmogenesis. This is in sharp contrast to the findings concerning ventricular arrhythmogenecity.
###end p 76
###begin p 77
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 219 224 <span type="species:ncbi:10090">mouse</span>
Furthermore, we demonstrated that the pharmacological agents described above exerted differing actions on arrhythmogenecity in the atria when these were compared to their known ventricular effects whether in WT and KPQ mouse hearts. Thus, both flecainide and quinidine reduced or completely eliminated atrial arrhythmogenesis in KPQ and WT groups. This was in contrast to the action of flecainide in reducing and that of quinidine in increasing ventricular arrhythmogencity in KPQ hearts while having the opposite effects in WT preparations [39, 40].
###end p 77
###begin p 78
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
To account for the differences observed in atria and ventricles of the same mouse model of LQT3, we went on to compare particular electrophysiological properties of the WT and KPQ hearts. Firstly, previous reports have implicated the ERP in atrial as opposed to ventricular arrhythmogenicity. Thus, decreases in atrial tissue refractoriness and APD are associated with atrial arrhythmogenesis [1, 6, 7, 22, 24, 33, 45, 48]. The present experiments similarly associated atrial arrhythmogenicity with short ERPs. Thus, arrhythmogenic WT hearts had significantly shorter ERPs when compared to the significantly less arrhythmogenic KPQ hearts. This is in contrast to findings in the ventricles in which non-arrhythmogenic WT hearts had shorter ventricular ERPs when compared to arrhythmogenic KPQ preparations [40]. Furthermore, we observed that flecainide and quinidine significantly increased the ERP in both WT and KPQ groups in parallel with their reducing or completely eliminating atrial arrhythmic episodes in both genetic variants. Again, this contrasts with the findings in the ventricles, in which the repolarisation gradient across the ventricular wall was a more consistent predictor of ventricular arrhythmogeneity than differences in ERP.
###end p 78
###begin p 79
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 462 464 462 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 580 582 580 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 858 860 858 860 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1109 1111 1109 1111 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 1281 1282 1281 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 277 282 <span type="species:ncbi:10090">mouse</span>
###xml 768 774 <span type="species:ncbi:10090">murine</span>
However, despite a number of studies showing that ventricular arrhythmogenicity in LQTS is associated with changes in electrical gradient across the ventricular wall [20, 35, 36], a recent study by Sabir et al. established another predictor of such arrhythmias in hypokaleimic mouse hearts [27]. It demonstrated increased tendencies to local re-excitation and arrhythmogenicity when recovery of the action potential, measured by its duration at 90% recovery (APD90), exceeded the corresponding recovery of excitability, as measured by the VERP. The difference between the two (APD90-VERP) was represented as a CI. Positive shifts in CI reflected a relatively proarrhythmic state, whereas negative shifts reflected an antiarrhythmic state. We tested this hypothesis in murine atria. Accordingly, we measured atrial effective refractory periods (AERPs) and APD90s both before and during pharmacological intervention to obtain atrial CIs for each test condition in both experimental groups. Our study demonstrated that in the absence of pharmacological agents the atria of arrhythmogenic WT hearts had larger APD90 values when compared to their AERP, thus giving a positive CI. Furthermore, such baseline recordings showed that WT hearts had a significantly larger positive CI value (P < 0.001) when compared to KPQ hearts. This correlated with greater atrial arrhythmic tendency of the WT preparations.
###end p 79
###begin p 80
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
Furthermore, both flecainide and quinidine were anti-arrhythmic in either experimental group and produced significant negative shifts in CI, especially with flecainide. These findings fulfil expectations from similar reports of altered ventricular as opposed to atrial arrhythmogenecity under particular circumstances. Under normal conditions, local VERP closely corresponds to APD. Thus, previous studies in ventricles from a range of species reported that manoeuvres that alter APD also result in corresponding changes in VERPs [10, 17, 18]. During PES, a premature extrastimulus shortens RP to a larger extent than APD, which in turn can induce ventricular arrhythmias [18]. Conversely, Class I cardiotropic drugs could either suppress or initiate ventricular arrhythmogenesis by altering the ERP/APD ratio through selective changes in one or other parameter thereby modifiying post-repolarisation refractoriness (PRR) [13, 16]. They then would also be expected to exert corresponding effects on atrial arrhythmogenecity.
###end p 80
###begin p 81
###xml 213 215 213 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 528 530 528 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 376 381 <span type="species:ncbi:9606">human</span>
###xml 547 552 <span type="species:ncbi:9606">human</span>
The present studies demonstrated that flecainide exerted anti-arrhythmic effects. That could also be correlated with the present findings concerning changes in CI. Thus, flecainide only significantly increased APD90 in WT but increased AERP in both WT and KPQ. The result was a negative CI, These results are in agreement with previous findings on the effect of flecainide in human atria. For example, Kirchholf et al (2005) [15] demonstrated that flecainide induced post recovery refractoriness by prolonging AERP more than APD90 in fibrillating human atrium and prevented arrhythmia reoccurrence after electrical cardioversion.
###end p 81
###begin p 82
###xml 154 156 154 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">90</sub>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 861 863 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 439 444 <span type="species:ncbi:9606">human</span>
Quinidine also decreased arrhythmogenic tendency in both WT and KPQ hearts, although to a smaller extent than did flecainide. Quinidine increased both APD90 and AERP, but exerted a greater effect on AERP, thereby resulting in a negative CI value, again to a lesser extent than shown in the presence of flecainide. These findings parallel the effects of quinidine on ventricular arrhythmogenesis. Thus, quinidine can promote development of human ventricular arrhythmia especially during bradycardia by prolonging repolarisation (APD) and not refractoriness [23, 26]. On the other hand, once arrhythmia has been initiated after quinidine administration, it can often be suppressed by pacing the heart at high rates [26]. This can be attributed to it having a more marked effect on VERP than on APD with increasing heart rate resulting in a protective effect [23, 11].
###end p 82
###begin p 83
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 229 231 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
In summary, this study compared for the first time the effects of flecainide and quinidine on the electrophysiological properties of WT and genetically modified (Scn5a+/Delta) mice lacking the same KPQ residues as LQT3 patients [25]. It appears that KPQ mutation, while predisposing to ventricular arrhythmias, has a 'protective' effect for atrial arrhythmogenicity. Therefore, our investigation shows that factors previously known to determine arrhythmias in ventricles do not necessarily determine atrial arrhythmogenic tendency. Nevertheless, the present findings bearing on atrial arrhythmogenecity could be correlated with corresponding criteria developed for ventricular arrhythmogenesis in one important respect: prolonging RP beyond APD may be beneficial for prevention of atrial arrhythmias. Therefore, agents that promote post recovery refractoriness and shift CI in the negative direction may be a good target for development of drugs aimed at preventing atrial arrhythmogenesis.
###end p 83
###begin title 84
Acknowledgements
###end title 84
###begin p 85
We thank the James Baird Fund, the Frank Elmore Fund, the Medical Research Council, the Wellcome Trust and the British Heart Foundation, UK, and the National Natural Science Foundation of China (NSFC 30371571 and 30672209), PRC for their generous support.
###end p 85
###begin p 86
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 86
###begin title 87
References
###end title 87
###begin article-title 88
Pathophysiology and prevention of atrial fibrillation
###end article-title 88
###begin article-title 89
Basic mechanisms of re-entrant arrhythmias
###end article-title 89
###begin article-title 90
Amplification of spatial dispersion of repolarisation underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes
###end article-title 90
###begin article-title 91
Cellular mechanisms underlying the long QT syndrome
###end article-title 91
###begin article-title 92
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1
###end article-title 92
###begin article-title 93
KCNQ1 gain-of-function mutation in familial atrial fibrillation
###end article-title 93
###begin article-title 94
Acetylcholine release by a stimulus train lowers atrial fibrillation threthold
###end article-title 94
###begin article-title 95
###xml 92 97 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCN5A</italic>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice
###end article-title 95
###begin article-title 96
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring
###end article-title 96
###begin article-title 97
A new single catheter technique for simultaneous measurement of action potential duration and refractory period in vivo
###end article-title 97
###begin article-title 98
Frequency-dependent effects of quinidine on the relationship between action potential duration and refractoriness in the canine heart in situ
###end article-title 98
###begin article-title 99
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Paced electrogram fractionation analysis of arrhythmogenic tendency in DeltaKPQ Scn5a mice
###end article-title 99
###begin article-title 100
Amiodarone-induced post-repolarization refractoriness suppresses induction of ventricular fibrillation
###end article-title 100
###begin article-title 101
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome
###end article-title 101
###begin article-title 102
###xml 62 67 <span type="species:ncbi:9606">human</span>
Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation
###end article-title 102
###begin article-title 103
Post-repolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs - antiarrhythmic and proarrhythmic effects
###end article-title 103
###begin article-title 104
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
Monophasic action potential recordings from intact mouse heart: Validation, regional heterogeneity, and relation to refractoriness
###end article-title 104
###begin article-title 105
###xml 99 104 <span type="species:ncbi:9606">human</span>
Relation between repolarization and refractoriness during programmed electrical stimulation in the human right ventricle. Implications for ventricular tachycardia induction
###end article-title 105
###begin article-title 106
###xml 65 70 <span type="species:ncbi:10090">mouse</span>
Evaluation of the role of I(KACh) in atrial fibrillation using a mouse knockout model
###end article-title 106
###begin article-title 107
Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3
###end article-title 107
###begin article-title 108
On the multiple wavelet hypothesis of atrial fibrillation
###end article-title 108
###begin article-title 109
Role of the sinus node in the mechanism of cholinergic atrial fibrillation
###end article-title 109
###begin article-title 110
###xml 97 103 <span type="species:ncbi:9606">humans</span>
Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans
###end article-title 110
###begin article-title 111
New ideas about atrial fibrillation 50 years on
###end article-title 111
###begin article-title 112
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome
###end article-title 112
###begin article-title 113
Clinical features and basic mechanisms of quindine-induced arrhythmias
###end article-title 113
###begin article-title 114
###xml 95 101 <span type="species:ncbi:10090">murine</span>
The contribution of refractoriness to arrhythmic substrate in hypokalemic Langendorff-perfused murine hearts
###end article-title 114
###begin article-title 115
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse models of long QT syndrome
###end article-title 115
###begin article-title 116
###xml 114 116 114 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Ks</sub>
###xml 128 133 <span type="species:ncbi:10090">mouse</span>
Adrenergic regulation of a key cardiac potassium channel can contribute to atrial fibrillation: evidence from an IKs transgenic mouse
###end article-title 116
###begin article-title 117
Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation
###end article-title 117
###begin article-title 118
Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases
###end article-title 118
###begin article-title 119
###xml 79 94 <span type="species:ncbi:10090">transgenic mice</span>
Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor
###end article-title 119
###begin article-title 120
Cholinergically mediated tachyarrhythmias induced by a single extrastimulus in the isolated canine right atrium
###end article-title 120
###begin article-title 121
Cellular and ionic basis for T-wave alternans under long-QT conditions
###end article-title 121
###begin article-title 122
Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes
###end article-title 122
###begin article-title 123
Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome
###end article-title 123
###begin article-title 124
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation
###end article-title 124
###begin article-title 125
Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2
###end article-title 125
###begin article-title 126
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 77 83 <span type="species:ncbi:10090">murine</span>
Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/- murine hearts modelling the Brugada syndrome
###end article-title 126
###begin article-title 127
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scn5a</italic>
###xml 81 87 <span type="species:ncbi:10090">murine</span>
Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3
###end article-title 127
###begin article-title 128
Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes
###end article-title 128
###begin article-title 129
###xml 34 38 <span type="species:ncbi:10090">mice</span>
Atrial fibrillation in KCNE1-null mice
###end article-title 129
###begin article-title 130
Atrial arrhythmias in the inherited long QT syndrome: Laboratory quirk or clinical arrhythmia
###end article-title 130
###begin article-title 131
Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: Time to revise current concepts
###end article-title 131
###begin article-title 132
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
Induction of atrial tachycardia and fibrillation in the mouse heart
###end article-title 132
###begin article-title 133
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia
###end article-title 133
###begin article-title 134
SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome
###end article-title 134
###begin article-title 135
###xml 90 95 <span type="species:ncbi:9925">goats</span>
Atrial fibrillation begets atrial fibrillation: A study on awake chronically instrumented goats
###end article-title 135

